Identification

Name
Hydrocortisone
Accession Number
DB00741  (APRD01019, DB07886)
Type
Small Molecule
Groups
Approved, Vet approved
Description

The main glucocorticoid secreted by the adrenal cortex. Its synthetic counterpart is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions.

Structure
Thumb
Synonyms
  • (11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
  • 11beta-hydrocortisone
  • 11beta,17alpha,21-Trihydroxy-4-pregnene-3,20-dione
  • 11β-hydrocortisone
  • 17-Hydroxycorticosterone
  • 4-pregnen-11β,17α,21-triol-3,20-dione
  • Cortisol
  • Hidrocortisona
  • Hydrocortisonum
  • Kendall's compound F
  • Reichstein's substance M
External IDs
NSC-10483
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
A-hydrocort Inj 1000mg/8mlPowder, for solution1 gIntramuscular; IntravenousHospira, Inc.1993-12-312012-08-03Canada
A-hydrocort Inj 100mg/2mlPowder, for solution100 mgIntramuscular; IntravenousHospira, Inc.1992-12-312012-08-03Canada
A-hydrocort Inj 250mg/2mlPowder, for solution250 mgIntramuscular; IntravenousHospira, Inc.1992-12-312012-08-03Canada
A-hydrocort Inj 500mg/4mlPowder, for solution500 mgIntramuscular; IntravenousHospira, Inc.1992-12-312012-08-03Canada
Aquacort Lotion 2.5%Lotion2.5 %TopicalMerit Industries Inc.1992-12-312002-05-14Canada
Barriere HC 1%Cream; Jelly1 %TopicalAllen & Hanburys A Glaxo Canada Ltd. Co.1979-12-311998-07-29Canada
Cortate Crm 1%Cream10 mgTopicalSchering Plough1980-12-312013-07-31Canada
Cortate Ont 1%Ointment10 mgTopicalSchering Plough1980-12-312013-07-31Canada
CortefTablet5 mg/1OralPharmacia & Upjohn Inc1952-12-15Not applicableUs
CortefTablet20 mg/1OralPharmacia & Upjohn Inc1952-12-15Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AlacortCream10 mg/gTopicalCrown Laboratories1973-03-09Not applicableUs
AlacortCream25 mg/gTopicalCrown Laboratories1973-03-09Not applicableUs
Anusol HCCream25 mg/gTopicalSalix Pharmaceuticals1984-06-06Not applicableUs
ColocortSuspension100 mg/60mLRectalPaddock Laboratories, Inc.1999-12-31Not applicableUs
Home PapKitCream25 mg/gTopicalInternational Brand Management, Llc2016-09-15Not applicableUs
HydrocortisoneTablet20 mg/1OralWest Ward Pharmaceutical1973-06-18Not applicableUs
HydrocortisoneTablet20 mg/1OralPd Rx Pharmaceuticals, Inc.1973-06-18Not applicableUs00143 1254 01 nlmimage10 ed0776db
HydrocortisoneCream10 mg/gTopicalActavis Pharma Company2002-01-03Not applicableUs
HydrocortisoneCream10 mg/gTopicalANI Pharmaceuticals, Inc.2016-04-01Not applicableUs
HydrocortisoneTablet10 mg/1OralLineage Therapeutics2007-03-30Not applicableUs54505 0332 10 nlmimage10 123b891c
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
1% HydrocortisoneCream1 g/100gTopicalYuyao Jessie Commodity Co.,Ltd.2015-12-01Not applicableUs
999 Itch RelievingOintment1 g/100gTopicalGuangdong CR. Shunfeng Pharmaceutical Co Ltd1989-07-20Not applicableUs
999 Itch RelievingOintment1 g/100gTopicalGuangdong CR. Shunfeng Pharmaceutical Co Ltd1989-07-20Not applicableUs
Advanced HydrocortisoneCream10 mg/gTopicalUltra Seal Corporation2011-04-05Not applicableUs
Ana Cool Rapid Soothing Cooling FormulaCream10 mg/gTopicalAna Cool, Llc2015-11-25Not applicableUs
Anti ItchLotion1 g/100gTopicalWalgreen2012-03-27Not applicableUs
Anti ItchOintment1 g/100gTopicalRite Aid2005-07-25Not applicableUs
Anti ItchCream1 g/100gTopicalSafeway2005-08-24Not applicableUs
Anti ItchCream1 g/100gTopicalHyvee2015-11-01Not applicableUs
Anti ItchCream1 g/100gTopicalRite Aid2013-09-11Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Acetasol HCHydrocortisone (1.1 g/100mL) + Acetic acid (2.41 g/100mL)SolutionAuricular (otic)Actavis Pharma Company2002-09-10Not applicableUs
Antibiotic Ear (Neo/Polym/HC)Hydrocortisone (10 mg/mL) + Neomycin sulfate (3.5 mg/mL) + Polymyxin B Sulfate (10000 [USP'U]/mL)Solution / dropsAuricular (otic)Physicians Total Care, Inc.1995-12-29Not applicableUs
Calmurid HC CrmHydrocortisone (10 mg) + Urea (100 mg)CreamTopicalGalderma1994-12-312000-08-02Canada
CiproHydrocortisone (10 mg/1mL) + Benzyl alcohol (9 mg/1mL) + Ciprofloxacin hydrochloride (2 mg/1mL)SuspensionAuricular (otic)Physicians Total Care, Inc.2009-02-12Not applicableUs
Cipro HCHydrocortisone (10 mg/mL) + Ciprofloxacin hydrochloride (2 mg/mL)SuspensionAuricular (otic)Alcon, Inc.1999-03-15Not applicableUs
Cipro HCHydrocortisone (10 mg/mL) + Benzyl alcohol (9 mg/mL) + Ciprofloxacin (2 mg/mL)SuspensionAuricular (otic)Stat Rx USA1998-02-102018-02-08Us
Cipro HCHydrocortisone (10 mg/mL) + Ciprofloxacin hydrochloride (2 mg/mL)SuspensionAuricular (otic)A S Medication Solutions1999-03-152017-06-20Us
Cipro HC Otic SuspensionHydrocortisone (10 mg) + Ciprofloxacin (2 mg)SuspensionAuricular (otic)Alcon, Inc.1999-06-222008-12-08Canada
CortisporinHydrocortisone (10 mg) + Bacitracin zinc (400 unit) + Neomycin sulfate (5 mg) + Polymyxin B Sulfate (10000 unit)OintmentOphthalmicGlaxosmithkline Inc1989-12-312002-07-31Canada
CortisporinHydrocortisone (10 mg) + Bacitracin (400 unit) + Neomycin (5 mg) + Polymyxin B Sulfate (5000 unit)OintmentTopicalGlaxosmithkline Inc1986-12-312014-11-03Canada
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Ala QuinHydrocortisone (5 mg/g) + Clioquinol (30 mg/g)CreamTopicalCrown Laboratories1970-08-19Not applicableUs
AlcortinHydrocortisone (2 g/100g) + Diiodohydroxyquinoline (1 g/100g)GelTopicalPrimus Pharmaceuticals2003-07-25Not applicableUs
Cortane-BHydrocortisone (10 mg/mL) + Chloroxylenol (1 mg/mL) + Pramoxine hydrochloride (10 mg/mL)LotionTopicalBlansett Pharmacal Co2017-03-20Not applicableUs
DermazeneHydrocortisone (10 mg/g) + Diiodohydroxyquinoline (10 mg/g)CreamTopicalStratus Pharmaceuticals2001-06-11Not applicableUs
Dr. Throwers HydrotetHydrocortisone (1 g/100g) + Tretinoin (.05 g/100g)CreamTopicalDr. Thrower's Skincare, Inc.2015-05-15Not applicableUs
FIRST Dukes Mouthwash CompoundingHydrocortisone + Diphenhydramine hydrochloride + NystatinKitOralCutis Pharma, Inc.2010-12-152017-10-04Us
FIRST Marys Mouthwash CompoundingHydrocortisone + Diphenhydramine hydrochloride + Nystatin + Tetracycline hydrochlorideKitOralCutis Pharma, Inc.2010-12-152017-10-04Us
HydrocortisoneHydrocortisone (1 g/100mL)ShampooTopicalDr Marder Skincare Llc2017-06-14Not applicableUs
hydrocortisone IodoquinolHydrocortisone (10 mg/g) + Diiodohydroxyquinoline (10 mg/g)CreamTopicalPerrigo New York Inc.2008-07-14Not applicableUs
Pramoxine-HCHydrocortisone (10 mg/mL) + Chloroxylenol (1 mg/mL) + Pramoxine hydrochloride (10 mg/mL)Solution / dropsAuricular (otic)Ascend Laboratories, LLC2011-09-262016-04-05Us
International/Other Brands
Acticort / Aeroseb HC / Ala-Scalp / Algicirtis / Aquanil HC / Beta-HC / Cetacort / Cortaid / Delacort / Ficortril / Genacort / Glycort / Komed HC / Lacticare HC / Lubricort / Medicort / Meusicort / Micort-HC / Mildison / Nogenic HC / Nutracort / Nystaform-HC / Otocort / Penecort / Permicort / Polcort H / Preparation H Hydrocortisone Cream / Prepcort / Prevex HC / Proctocort / Proctocream / Protocort / Remederm HC / Sanatison / Scalpicin Capilar / Schericur / Sigmacort / Synacort / Systral Hydrocort / Timocort
Categories
UNII
WI4X0X7BPJ
CAS number
50-23-7
Weight
Average: 362.4599
Monoisotopic: 362.20932407
Chemical Formula
C21H30O5
InChI Key
JYGXADMDTFJGBT-VWUMJDOOSA-N
InChI
InChI=1S/C21H30O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h9,14-16,18,22,24,26H,3-8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1
IUPAC Name
(1R,3aS,3bS,9aR,9bS,10S,11aS)-1,10-dihydroxy-1-(2-hydroxyacetyl)-9a,11a-dimethyl-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-7-one
SMILES
[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C

Pharmacology

Indication

For the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Also used to treat endocrine (hormonal) disorders (adrenal insufficiency, Addisons disease). It is also used to treat many immune and allergic disorders, such as arthritis, lupus, severe psoriasis, severe asthma, ulcerative colitis, and Crohn's disease.

Associated Conditions
Pharmacodynamics

Hydrocortisone is the most important human glucocorticoid. It is essential for life and regulates or supports a variety of important cardiovascular, metabolic, immunologic and homeostatic functions. Topical hydrocortisone is used for its anti-inflammatory or immunosuppressive properties to treat inflammation due to corticosteroid-responsive dermatoses. Glucocorticoids are a class of steroid hormones characterised by an ability to bind with the cortisol receptor and trigger a variety of important cardiovascular, metabolic, immunologic and homeostatic effects. Glucocorticoids are distinguished from mineralocorticoids and sex steroids by having different receptors, target cells, and effects. Technically, the term corticosteroid refers to both glucocorticoids and mineralocorticoids, but is often used as a synonym for glucocorticoid. Glucocorticoids suppress cell-mediated immunity. They act by inhibiting genes that code for the cytokines IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-8 and TNF-alpha, the most important of which is the IL-2. Reduced cytokine production limits T cell proliferation. Glucocorticoids also suppress humoral immunity, causing B cells to express lower amounts of IL-2 and IL-2 receptors. This diminishes both B cell clonal expansion and antibody synthesis. The diminished amounts of IL-2 also leads to fewer T lymphocyte cells being activated.

Mechanism of action

Hydrocortisone binds to the cytosolic glucocorticoid receptor. After binding the receptor the newly formed receptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes preventing the phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products in inflammation Prostaglandins and Leukotrienes are inhibited by the action of Glucocorticoids. Glucocorticoids also stimulate the lipocortin-1 escaping to the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines etc.) from neutrophils, macrophages and mastocytes. Additionally the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.

TargetActionsOrganism
AGlucocorticoid receptor
agonist
Human
AAnnexin A1
agonist
Human
UCorticosteroid 11-beta-dehydrogenase isozyme 2Not AvailableHuman
U3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1Not AvailableHuman
Absorption

Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption.

Volume of distribution
Not Available
Protein binding

95%

Metabolism

Primarily hepatic via CYP3A4

Route of elimination

Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.

Half life

6-8 hours

Clearance
Not Available
Toxicity

Side effects include inhibition of bone formation, suppression of calcium absorption and delayed wound healing

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Corticosterone Methyl Oxidase II Deficiency (CMO II)Disease
Adrenal Hyperplasia Type 5 or Congenital Adrenal Hyperplasia Due to 17 alpha-Hydroxylase DeficiencyDisease
17-alpha-Hydroxylase Deficiency (CYP17)Disease
Adrenal Hyperplasia Type 3 or Congenital Adrenal Hyperplasia Due to 21-Hydroxylase DeficiencyDisease
Corticosterone Methyl Oxidase I Deficiency (CMO I)Disease
11-beta-Hydroxylase Deficiency (CYP11B1)Disease
21-Hydroxylase Deficiency (CYP21)Disease
3-beta-Hydroxysteroid Dehydrogenase DeficiencyDisease
SteroidogenesisMetabolic
Corticotropin Activation of Cortisol ProductionSignaling
Congenital Lipoid Adrenal Hyperplasia (CLAH) or Lipoid CAHDisease
Apparent Mineralocorticoid Excess SyndromeDisease
SteroidogenesisMetabolic
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1-TestosteroneThe risk or severity of edema formation can be increased when 1-Testosterone is combined with Hydrocortisone.Experimental, Illicit, Investigational
1,10-PhenanthrolineThe therapeutic efficacy of 1,10-Phenanthroline can be decreased when used in combination with Hydrocortisone.Experimental
16-BromoepiandrosteroneThe risk or severity of edema formation can be increased when 16-Bromoepiandrosterone is combined with Hydrocortisone.Investigational
19-norandrostenedioneThe risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Hydrocortisone.Experimental, Illicit
1alpha-Hydroxyvitamin D5The therapeutic efficacy of 1alpha-Hydroxyvitamin D5 can be decreased when used in combination with Hydrocortisone.Investigational
2-MethoxyethanolThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with 2-Methoxyethanol.Experimental
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Hydrocortisone.Investigational
4-HydroxytestosteroneThe risk or severity of edema formation can be increased when 4-Hydroxytestosterone is combined with Hydrocortisone.Experimental, Illicit
5-androstenedioneThe risk or severity of edema formation can be increased when 5-androstenedione is combined with Hydrocortisone.Experimental, Illicit
9-(N-methyl-L-isoleucine)-cyclosporin AThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.Investigational
AbataceptThe risk or severity of adverse effects can be increased when Abatacept is combined with Hydrocortisone.Approved
AbediterolThe risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Abediterol.Investigational
AbemaciclibThe serum concentration of Hydrocortisone can be increased when it is combined with Abemaciclib.Approved, Investigational
AbetimusThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Abetimus.Investigational
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Hydrocortisone.Approved, Investigational
AceclofenacThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Acemetacin.Approved, Experimental, Investigational
AcetaminophenThe serum concentration of Hydrocortisone can be increased when it is combined with Acetaminophen.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Hydrocortisone.Approved, Investigational, Withdrawn
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Hydrocortisone.Approved, Vet Approved
ActeosideThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Acteoside.Investigational
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Hydrocortisone.Approved
AfatinibThe serum concentration of Hydrocortisone can be increased when it is combined with Afatinib.Approved
AfelimomabThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Afelimomab.Investigational
AICA ribonucleotideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Hydrocortisone.Experimental, Investigational
AlbendazoleThe serum concentration of Hydrocortisone can be increased when it is combined with Albendazole.Approved, Vet Approved
AlbiglutideThe therapeutic efficacy of Albiglutide can be decreased when used in combination with Hydrocortisone.Approved
AlclofenacThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Alclometasone.Approved
AlcuroniumThe risk or severity of myopathy and weakness can be increased when Alcuronium is combined with Hydrocortisone.Experimental
AldesleukinThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Aldesleukin.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Aldosterone.Experimental, Investigational
AlectinibThe serum concentration of Hydrocortisone can be increased when it is combined with Alectinib.Approved, Investigational
AlefaceptThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Alefacept.Approved, Investigational, Withdrawn
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Hydrocortisone.Approved, Investigational
AlfacalcidolThe therapeutic efficacy of Alfacalcidol can be decreased when used in combination with Hydrocortisone.Approved, Nutraceutical
AlmasilateThe bioavailability of Hydrocortisone can be decreased when combined with Almasilate.Approved, Experimental
AlminoprofenThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Alminoprofen.Experimental
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Hydrocortisone.Approved
AloglutamolThe bioavailability of Hydrocortisone can be decreased when combined with Aloglutamol.Approved
AloxiprinThe risk or severity of adverse effects can be increased when Aloxiprin is combined with Hydrocortisone.Experimental
AltretamineThe risk or severity of adverse effects can be increased when Altretamine is combined with Hydrocortisone.Approved
AluminiumThe bioavailability of Hydrocortisone can be decreased when combined with Aluminium.Approved, Investigational
Aluminium acetoacetateThe bioavailability of Hydrocortisone can be decreased when combined with Aluminium acetoacetate.Experimental
Aluminium glycinateThe bioavailability of Hydrocortisone can be decreased when combined with Aluminium glycinate.Experimental
Aluminium phosphateThe bioavailability of Hydrocortisone can be decreased when combined with Aluminium phosphate.Approved, Investigational
Aluminum hydroxideThe bioavailability of Hydrocortisone can be decreased when combined with Aluminum hydroxide.Approved, Investigational
AmbenoniumThe therapeutic efficacy of Ambenonium can be decreased when used in combination with Hydrocortisone.Approved
AmcinonideThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Amcinonide.Approved
AMG-222The therapeutic efficacy of AMG-222 can be decreased when used in combination with Hydrocortisone.Investigational
AminophenazoneThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Aminophenazone.Approved, Withdrawn
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Hydrocortisone.Approved
AmiodaroneThe serum concentration of Hydrocortisone can be increased when it is combined with Amiodarone.Approved, Investigational
AmlodipineThe serum concentration of Hydrocortisone can be increased when it is combined with Amlodipine.Approved
AmodiaquineThe serum concentration of Hydrocortisone can be increased when it is combined with Amodiaquine.Approved, Investigational
AmoxapineThe serum concentration of Hydrocortisone can be increased when it is combined with Amoxapine.Approved
Amphotericin BThe risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Amphotericin B.Approved, Investigational
AmprenavirThe metabolism of Hydrocortisone can be decreased when combined with Amprenavir.Approved, Investigational
AmsacrineThe risk or severity of adverse effects can be increased when Amsacrine is combined with Hydrocortisone.Approved, Investigational
AnagliptinThe therapeutic efficacy of Anagliptin can be decreased when used in combination with Hydrocortisone.Investigational
AnakinraThe risk or severity of adverse effects can be increased when Anakinra is combined with Hydrocortisone.Approved
AndrostenediolThe risk or severity of edema formation can be increased when Androstenediol is combined with Hydrocortisone.Experimental, Illicit
AndrostenedioneThe risk or severity of edema formation can be increased when Androstenedione is combined with Hydrocortisone.Experimental, Illicit
AnnamycinThe serum concentration of Hydrocortisone can be increased when it is combined with Annamycin.Investigational
Anthrax immune globulin humanThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Hydrocortisone.Approved
Anthrax vaccineThe risk or severity of infection can be increased when Anthrax vaccine is combined with Hydrocortisone.Approved
Anthrax vaccineThe therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Hydrocortisone.Approved
Antilymphocyte immunoglobulin (horse)The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Hydrocortisone.Approved, Investigational
AntipyrineThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Antipyrine.Approved, Investigational
Antithymocyte immunoglobulin (rabbit)The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Hydrocortisone.Approved
AntrafenineThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Antrafenine.Approved
ApalutamideThe serum concentration of Hydrocortisone can be decreased when it is combined with Apalutamide.Approved, Investigational
ApremilastThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Apremilast.Approved, Investigational
AprepitantThe serum concentration of Hydrocortisone can be increased when it is combined with Aprepitant.Approved, Investigational
ArbutamineThe risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Arbutamine.Approved
ArformoterolThe risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Arformoterol.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Hydrocortisone.Approved, Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Arsenic trioxide.Approved, Investigational
AstemizoleThe serum concentration of Hydrocortisone can be increased when it is combined with Astemizole.Approved, Withdrawn
AsunaprevirThe serum concentration of Asunaprevir can be decreased when it is combined with Hydrocortisone.Approved, Investigational, Withdrawn
AtamestaneThe risk or severity of edema formation can be increased when Atamestane is combined with Hydrocortisone.Investigational
AtazanavirThe metabolism of Hydrocortisone can be decreased when combined with Atazanavir.Approved, Investigational
AtorvastatinThe serum concentration of Hydrocortisone can be increased when it is combined with Atorvastatin.Approved
AtracuriumThe risk or severity of myopathy and weakness can be increased when Atracurium is combined with Hydrocortisone.Approved, Experimental, Investigational
Atracurium besylateThe risk or severity of myopathy and weakness can be increased when Atracurium besylate is combined with Hydrocortisone.Approved
AzacitidineThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Azacitidine.Approved, Investigational
AzapropazoneThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Azapropazone.Withdrawn
AzathioprineThe risk or severity of adverse effects can be increased when Azathioprine is combined with Hydrocortisone.Approved
AzelastineThe serum concentration of Hydrocortisone can be increased when it is combined with Azelastine.Approved
AzithromycinThe serum concentration of Hydrocortisone can be increased when it is combined with Azithromycin.Approved
AzosemideThe risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Azosemide.Investigational
Bacillus calmette-guerin substrain connaught live antigenThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Hydrocortisone.Approved, Investigational
Bacillus calmette-guerin substrain connaught live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Hydrocortisone.Approved, Investigational
Bacillus calmette-guerin substrain danish 1331 live antigenThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Hydrocortisone.Investigational
Bacillus calmette-guerin substrain danish 1331 live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain danish 1331 live antigen can be decreased when used in combination with Hydrocortisone.Investigational
Bacillus calmette-guerin substrain tice live antigenThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Hydrocortisone.Approved
Bacillus calmette-guerin substrain tice live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Hydrocortisone.Approved
Bafilomycin A1The serum concentration of Hydrocortisone can be increased when it is combined with Bafilomycin A1.Experimental
Bafilomycin B1The serum concentration of Hydrocortisone can be increased when it is combined with Bafilomycin B1.Experimental
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Hydrocortisone.Investigational
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Hydrocortisone.Approved, Investigational
BambuterolThe risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Bambuterol.Approved, Investigational
BasiliximabThe risk or severity of adverse effects can be increased when Basiliximab is combined with Hydrocortisone.Approved, Investigational
BCG vaccineThe risk or severity of infection can be increased when BCG vaccine is combined with Hydrocortisone.Investigational
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Hydrocortisone.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Beclomethasone dipropionate.Approved, Investigational
BecocalcidiolThe therapeutic efficacy of Becocalcidiol can be decreased when used in combination with Hydrocortisone.Investigational
BegelomabThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Begelomab.Experimental, Investigational
BelataceptThe risk or severity of adverse effects can be increased when Belatacept is combined with Hydrocortisone.Approved, Investigational
BelimumabThe risk or severity of adverse effects can be increased when Belimumab is combined with Hydrocortisone.Approved
BelinostatThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Belinostat.Approved, Investigational
Bempedoic acidThe therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Hydrocortisone.Investigational
BendamustineThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Bendamustine.Approved, Investigational
BendazacThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Bendazac.Experimental
BendroflumethiazideHydrocortisone may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenfluorexThe therapeutic efficacy of Benfluorex can be decreased when used in combination with Hydrocortisone.Investigational, Withdrawn
BenorilateThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Benoxaprofen.Withdrawn
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Hydrocortisone.Approved, Investigational
BenzquinamideThe serum concentration of Hydrocortisone can be increased when it is combined with Benzquinamide.Withdrawn
BenzthiazideHydrocortisone may increase the hypokalemic activities of Benzthiazide.Approved
BenzydamineThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Benzydamine.Approved
Benzyl alcoholThe serum concentration of Hydrocortisone can be increased when it is combined with Benzyl alcohol.Approved
BepridilThe serum concentration of Hydrocortisone can be increased when it is combined with Bepridil.Approved, Withdrawn
BesifloxacinThe risk or severity of tendinopathy can be increased when Hydrocortisone is combined with Besifloxacin.Approved
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Hydrocortisone.Approved, Vet Approved
BevacizumabThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Bevacizumab.Approved, Investigational
BexaroteneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Bexarotene.Approved, Investigational
BicalutamideThe metabolism of Hydrocortisone can be decreased when combined with Bicalutamide.Approved
Biricodar dicitrateThe serum concentration of Hydrocortisone can be increased when it is combined with Biricodar dicitrate.Investigational
Bismuth subnitrateThe bioavailability of Hydrocortisone can be decreased when combined with Bismuth subnitrate.Approved
BitolterolThe risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Bitolterol.Withdrawn
BleomycinThe risk or severity of adverse effects can be increased when Bleomycin is combined with Hydrocortisone.Approved, Investigational
BlinatumomabThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Blinatumomab.Approved, Investigational
BoceprevirThe metabolism of Hydrocortisone can be decreased when combined with Boceprevir.Approved, Withdrawn
BolandiolThe risk or severity of edema formation can be increased when Bolandiol is combined with Hydrocortisone.Experimental, Illicit
BolasteroneThe risk or severity of edema formation can be increased when Bolasterone is combined with Hydrocortisone.Experimental, Illicit
BoldenoneThe risk or severity of edema formation can be increased when Boldenone is combined with Hydrocortisone.Illicit, Vet Approved
BortezomibThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Hydrocortisone can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Hydrocortisone.Approved
Brefeldin AThe serum concentration of Hydrocortisone can be increased when it is combined with Brefeldin A.Experimental
Brentuximab vedotinThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Brentuximab vedotin.Approved, Investigational
BriakinumabThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Briakinumab.Investigational
BrodalumabThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Brodalumab.Approved, Investigational
BromfenacThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Bromfenac.Approved
BromocriptineThe metabolism of Bromocriptine can be decreased when combined with Hydrocortisone.Approved, Investigational
BudesonideThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Budesonide.Approved
BufexamacThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Bufexamac.Approved, Experimental
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Hydrocortisone.Investigational, Withdrawn
BumadizoneThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Bumadizone.Experimental
BumetanideThe risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Bumetanide.Approved
BuprenorphineThe serum concentration of Hydrocortisone can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe serum concentration of Hydrocortisone can be increased when it is combined with Buspirone.Approved, Investigational
BusulfanThe risk or severity of adverse effects can be increased when Busulfan is combined with Hydrocortisone.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Cabazitaxel.Approved
CabergolineThe metabolism of Cabergoline can be decreased when combined with Hydrocortisone.Approved
CaffeineThe serum concentration of Hydrocortisone can be increased when it is combined with Caffeine.Approved
CalcidiolThe therapeutic efficacy of Calcidiol can be decreased when used in combination with Hydrocortisone.Approved, Nutraceutical
CalcipotriolThe therapeutic efficacy of Calcipotriol can be decreased when used in combination with Hydrocortisone.Approved
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Hydrocortisone.Approved, Nutraceutical
Calcium CarbonateThe bioavailability of Hydrocortisone can be decreased when combined with Calcium Carbonate.Approved, Investigational
Calcium silicateThe bioavailability of Hydrocortisone can be decreased when combined with Calcium silicate.Experimental
CalusteroneThe risk or severity of edema formation can be increased when Calusterone is combined with Hydrocortisone.Experimental, Illicit
CanagliflozinThe serum concentration of Hydrocortisone can be increased when it is combined with Canagliflozin.Approved
CanakinumabThe risk or severity of adverse effects can be increased when Canakinumab is combined with Hydrocortisone.Approved, Investigational
CapecitabineThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Capecitabine.Approved, Investigational
Capromab pendetideHydrocortisone may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
CaptoprilThe serum concentration of Hydrocortisone can be increased when it is combined with Captopril.Approved
CarbamazepineThe serum concentration of Hydrocortisone can be decreased when it is combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Hydrocortisone.Experimental, Investigational
CarboplatinThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Carboplatin.Approved
CarbutamideThe therapeutic efficacy of Carbutamide can be decreased when used in combination with Hydrocortisone.Experimental
CarfilzomibThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Carfilzomib.Approved, Investigational
CarmegliptinThe therapeutic efficacy of Carmegliptin can be decreased when used in combination with Hydrocortisone.Investigational
CarmustineThe risk or severity of adverse effects can be increased when Carmustine is combined with Hydrocortisone.Approved, Investigational
CarprofenThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarvedilolThe serum concentration of Hydrocortisone can be increased when it is combined with Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Castanospermine.Experimental
CefoperazoneThe serum concentration of Hydrocortisone can be increased when it is combined with Cefoperazone.Approved, Investigational
CeftriaxoneThe serum concentration of Hydrocortisone can be increased when it is combined with Ceftriaxone.Approved
CelecoxibThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Celecoxib.Approved, Investigational
CeliprololThe risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Hydrocortisone can be increased when it is combined with Ceritinib.Approved
Certolizumab pegolThe risk or severity of adverse effects can be increased when Certolizumab pegol is combined with Hydrocortisone.Approved
ChlorambucilThe risk or severity of adverse effects can be increased when Chlorambucil is combined with Hydrocortisone.Approved
ChloramphenicolThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Chloramphenicol.Approved, Vet Approved
ChlormadinoneThe serum concentration of Hydrocortisone can be increased when it is combined with Chlormadinone.Experimental
ChloroformThe serum concentration of Hydrocortisone can be increased when it is combined with Chloroform.Vet Approved
ChlorothiazideHydrocortisone may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorpromazineThe serum concentration of Hydrocortisone can be increased when it is combined with Chlorpromazine.Approved, Investigational, Vet Approved
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Hydrocortisone.Approved, Investigational
ChlorprothixeneThe serum concentration of Hydrocortisone can be increased when it is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorthalidoneHydrocortisone may increase the hypokalemic activities of Chlorthalidone.Approved
CholecalciferolThe therapeutic efficacy of Cholecalciferol can be decreased when used in combination with Hydrocortisone.Approved, Nutraceutical
Choline magnesium trisalicylateThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Choline magnesium trisalicylate.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Ciclesonide.Approved, Investigational
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Hydrocortisone.Experimental
CimicoxibThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Cimicoxib.Investigational
CinoxacinThe risk or severity of tendinopathy can be increased when Hydrocortisone is combined with Cinoxacin.Approved, Investigational, Withdrawn
CiprofloxacinThe risk or severity of tendinopathy can be increased when Hydrocortisone is combined with Ciprofloxacin.Approved, Investigational
CisatracuriumThe risk or severity of myopathy and weakness can be increased when Cisatracurium is combined with Hydrocortisone.Approved
CisplatinThe risk or severity of adverse effects can be increased when Cisplatin is combined with Hydrocortisone.Approved
CladribineThe risk or severity of adverse effects can be increased when Cladribine is combined with Hydrocortisone.Approved, Investigational
ClarithromycinThe metabolism of Hydrocortisone can be decreased when combined with Clarithromycin.Approved
ClenbuterolThe risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Clenbuterol.Approved, Investigational, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Clobetasol.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Clocortolone.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Hydrocortisone.Approved, Investigational
ClofazimineThe serum concentration of Hydrocortisone can be increased when it is combined with Clofazimine.Approved, Investigational
ClomipramineThe serum concentration of Hydrocortisone can be increased when it is combined with Clomipramine.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Clonixin.Approved
CloprednolThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Cloprednol.Experimental
ClostebolThe risk or severity of edema formation can be increased when Clostebol is combined with Hydrocortisone.Experimental, Illicit
Clostridium tetani toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Hydrocortisone.Approved
ClotrimazoleThe metabolism of Hydrocortisone can be decreased when combined with Clotrimazole.Approved, Vet Approved
CobicistatThe metabolism of Hydrocortisone can be decreased when combined with Cobicistat.Approved
ColchicineThe serum concentration of Hydrocortisone can be increased when it is combined with Colchicine.Approved
Concanamycin AThe serum concentration of Hydrocortisone can be increased when it is combined with Concanamycin A.Experimental
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Hydrocortisone.Approved, Investigational
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Hydrocortisone.Approved
CorticotropinThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Corticotropin.Approved, Investigational, Vet Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Cortisone acetate.Approved, Investigational
CortivazolThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Cortivazol.Investigational
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Hydrocortisone.Approved
CoumaphosThe therapeutic efficacy of Coumaphos can be decreased when used in combination with Hydrocortisone.Vet Approved
CrizotinibThe serum concentration of Hydrocortisone can be increased when it is combined with Crizotinib.Approved
CurcuminThe metabolism of Hydrocortisone can be decreased when combined with Curcumin.Approved, Investigational
CyclopenthiazideHydrocortisone may increase the hypokalemic activities of Cyclopenthiazide.Experimental
CyclophosphamideThe risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Hydrocortisone.Approved, Investigational
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Hydrocortisone.Approved, Investigational, Vet Approved
CytarabineThe risk or severity of adverse effects can be increased when Cytarabine is combined with Hydrocortisone.Approved, Investigational
DabrafenibThe serum concentration of Hydrocortisone can be decreased when it is combined with Dabrafenib.Approved, Investigational
DacarbazineThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Dacarbazine.Approved, Investigational
DaclatasvirThe serum concentration of Hydrocortisone can be increased when it is combined with Daclatasvir.Approved, Investigational
DaclizumabThe risk or severity of adverse effects can be increased when Daclizumab is combined with Hydrocortisone.Investigational, Withdrawn
DactinomycinThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Dactinomycin.Approved, Investigational
DanazolThe risk or severity of fluid retention can be increased when Hydrocortisone is combined with Danazol.Approved
DapagliflozinThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Hydrocortisone.Approved
DarunavirThe metabolism of Hydrocortisone can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Hydrocortisone can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe risk or severity of adverse effects can be increased when Daunorubicin is combined with Hydrocortisone.Approved
DecamethoniumThe risk or severity of myopathy and weakness can be increased when Decamethonium is combined with Hydrocortisone.Approved
DecitabineThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Decitabine.Approved, Investigational
DeferasiroxThe serum concentration of Hydrocortisone can be decreased when it is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Deflazacort.Approved, Investigational
DelavirdineThe metabolism of Hydrocortisone can be decreased when combined with Delavirdine.Approved
DemecariumThe therapeutic efficacy of Demecarium can be decreased when used in combination with Hydrocortisone.Approved
DenosumabThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Denosumab.Approved
DeoxyspergualinThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Deoxyspergualin.Investigational
DersalazineThe risk or severity of adverse effects can be increased when Dersalazine is combined with Hydrocortisone.Investigational
DesipramineThe serum concentration of Hydrocortisone can be increased when it is combined with Desipramine.Approved, Investigational
DesmethylsertralineThe serum concentration of Hydrocortisone can be increased when it is combined with Desmethylsertraline.Experimental
DesogestrelThe serum concentration of Hydrocortisone can be increased when it is combined with Desogestrel.Approved
DesonideThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Desoximetasone.Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Dexamethasone isonicotinate.Vet Approved
DexibuprofenThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Dexibuprofen.Approved, Investigational
DexketoprofenThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Dexketoprofen.Approved, Investigational
DexniguldipineThe serum concentration of Hydrocortisone can be increased when it is combined with Dexniguldipine.Experimental
DexrazoxaneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Dexrazoxane.Approved, Withdrawn
DexverapamilThe serum concentration of Hydrocortisone can be increased when it is combined with Dexverapamil.Experimental
DichlorvosThe therapeutic efficacy of Dichlorvos can be decreased when used in combination with Hydrocortisone.Vet Approved
DiclofenacThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Diclofenac.Approved, Vet Approved
DienogestThe risk or severity of edema formation can be increased when Dienogest is combined with Hydrocortisone.Approved
Diethyl etherThe serum concentration of Hydrocortisone can be increased when it is combined with Diethyl ether.Experimental
DifenpiramideThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Diflorasone.Approved
DifloxacinThe risk or severity of tendinopathy can be increased when Hydrocortisone is combined with Difloxacin.Vet Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Hydrocortisone.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Difluprednate.Approved
DihydroergocornineThe metabolism of Dihydroergocornine can be decreased when combined with Hydrocortisone.Approved
DihydroergocristineThe metabolism of Dihydroergocristine can be decreased when combined with Hydrocortisone.Approved, Experimental
DihydroergocryptineThe metabolism of Dihydroergocryptine can be decreased when combined with Hydrocortisone.Experimental
DihydroergotamineThe metabolism of Dihydroergotamine can be decreased when combined with Hydrocortisone.Approved, Investigational
DihydrotachysterolThe therapeutic efficacy of Dihydrotachysterol can be decreased when used in combination with Hydrocortisone.Approved
DiltiazemThe metabolism of Hydrocortisone can be decreased when combined with Diltiazem.Approved, Investigational
Dimethyl fumarateThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Dimethyl fumarate.Approved, Investigational
DinutuximabThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Dinutuximab.Approved, Investigational
DipivefrinThe risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Dipivefrin.Approved
DipyridamoleThe serum concentration of Hydrocortisone can be increased when it is combined with Dipyridamole.Approved
DisopyramideThe therapeutic efficacy of Disopyramide can be decreased when used in combination with Hydrocortisone.Approved
DistigmineThe therapeutic efficacy of Distigmine can be decreased when used in combination with Hydrocortisone.Experimental
DobutamineThe risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Dobutamine.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Docetaxel.Approved, Investigational
DofequidarThe serum concentration of Hydrocortisone can be increased when it is combined with Dofequidar.Experimental, Investigational
DonepezilThe therapeutic efficacy of Donepezil can be decreased when used in combination with Hydrocortisone.Approved
DovitinibThe serum concentration of Hydrocortisone can be increased when it is combined with Dovitinib.Investigational
DoxacuriumThe risk or severity of myopathy and weakness can be increased when Doxacurium is combined with Hydrocortisone.Approved
DoxazosinThe serum concentration of Hydrocortisone can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Hydrocortisone can be increased when it is combined with Doxepin.Approved, Investigational
DoxercalciferolThe therapeutic efficacy of Doxercalciferol can be decreased when used in combination with Hydrocortisone.Approved
DoxifluridineThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Doxifluridine.Investigational
DoxofyllineThe risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Doxofylline.Approved, Investigational
DoxorubicinThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Hydrocortisone can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Hydrocortisone can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe serum concentration of Hydrocortisone can be increased when it is combined with Dronedarone.Approved
DrospirenoneThe serum concentration of Hydrocortisone can be increased when it is combined with Drospirenone.Approved
DroxicamThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Droxicam.Withdrawn
DroxidopaThe risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Droxidopa.Approved, Investigational
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Hydrocortisone.Approved, Investigational
DuloxetineThe serum concentration of Hydrocortisone can be increased when it is combined with Duloxetine.Approved
DutogliptinThe therapeutic efficacy of Dutogliptin can be decreased when used in combination with Hydrocortisone.Investigational
EchothiophateThe therapeutic efficacy of Echothiophate can be decreased when used in combination with Hydrocortisone.Approved
EconazoleThe serum concentration of Hydrocortisone can be increased when it is combined with Econazole.Approved
EculizumabThe risk or severity of adverse effects can be increased when Eculizumab is combined with Hydrocortisone.Approved, Investigational
EdrophoniumThe therapeutic efficacy of Edrophonium can be decreased when used in combination with Hydrocortisone.Approved
EfalizumabThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Efalizumab.Approved, Investigational
EfavirenzThe metabolism of Hydrocortisone can be decreased when combined with Efavirenz.Approved, Investigational
ElacridarThe serum concentration of Hydrocortisone can be increased when it is combined with Elacridar.Investigational
EldecalcitolThe therapeutic efficacy of Eldecalcitol can be decreased when used in combination with Hydrocortisone.Investigational
ElocalcitolThe therapeutic efficacy of Elocalcitol can be decreased when used in combination with Hydrocortisone.Investigational
EmopamilThe serum concentration of Hydrocortisone can be increased when it is combined with Emopamil.Experimental
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Hydrocortisone.Approved
EnasidenibThe serum concentration of Hydrocortisone can be increased when it is combined with Enasidenib.Approved, Investigational
EnglitazoneThe therapeutic efficacy of Englitazone can be decreased when used in combination with Hydrocortisone.Experimental
EnoxacinThe risk or severity of tendinopathy can be increased when Hydrocortisone is combined with Enoxacin.Approved, Investigational
EnzalutamideThe serum concentration of Hydrocortisone can be decreased when it is combined with Enzalutamide.Approved
EphedraThe risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Ephedra.Approved, Nutraceutical, Withdrawn
EpinephrineThe risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Epinephrine.Approved, Vet Approved
EpirizoleThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Epirizole.Approved
EpirubicinThe risk or severity of adverse effects can be increased when Epirubicin is combined with Hydrocortisone.Approved
EpitizideHydrocortisone may increase the hypokalemic activities of Epitizide.Experimental
ErgocalciferolThe therapeutic efficacy of Ergocalciferol can be decreased when used in combination with Hydrocortisone.Approved, Nutraceutical
Ergoloid mesylateThe metabolism of Ergoloid mesylate can be decreased when combined with Hydrocortisone.Approved
ErgonovineThe metabolism of Ergonovine can be decreased when combined with Hydrocortisone.Approved
ErgotamineThe metabolism of Ergotamine can be decreased when combined with Hydrocortisone.Approved
EribulinThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Eribulin.Approved, Investigational
ErlotinibThe serum concentration of Hydrocortisone can be increased when it is combined with Erlotinib.Approved, Investigational
ErythromycinThe serum concentration of Hydrocortisone can be increased when it is combined with Erythromycin.Approved, Investigational, Vet Approved
EsomeprazoleThe serum concentration of Hydrocortisone can be increased when it is combined with Esomeprazole.Approved, Investigational
EstradiolThe serum concentration of Hydrocortisone can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
EstramustineThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Estramustine.Approved, Investigational
Etacrynic acidThe risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Etacrynic acid.Approved, Investigational
EtafedrineThe risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Etafedrine.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Hydrocortisone.Approved, Investigational
EthenzamideThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Ethenzamide.Experimental
Ethinyl EstradiolThe serum concentration of Hydrocortisone can be increased when it is combined with Ethinyl Estradiol.Approved
EthynodiolThe serum concentration of Hydrocortisone can be increased when it is combined with Ethynodiol.Experimental
Ethynodiol diacetateThe serum concentration of Hydrocortisone can be increased when it is combined with Ethynodiol diacetate.Approved
EtodolacThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Etofenamate.Approved, Investigational
EtonogestrelThe serum concentration of Hydrocortisone can be increased when it is combined with Etonogestrel.Approved, Investigational
EtoposideThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Etoposide.Approved
EtoricoxibThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Etoricoxib.Approved, Investigational
EtravirineThe serum concentration of Hydrocortisone can be decreased when it is combined with Etravirine.Approved
EverolimusThe risk or severity of adverse effects can be increased when Everolimus is combined with Hydrocortisone.Approved
EvogliptinThe therapeutic efficacy of Evogliptin can be decreased when used in combination with Hydrocortisone.Investigational
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Hydrocortisone.Approved, Investigational
FelbinacThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Felbinac.Experimental
FelodipineThe serum concentration of Hydrocortisone can be increased when it is combined with Felodipine.Approved, Investigational
FenbufenThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Fenbufen.Approved
FenofibrateThe serum concentration of Hydrocortisone can be increased when it is combined with Fenofibrate.Approved
FenoprofenThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Fenoprofen.Approved
FenoterolThe risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Fenoterol.Approved, Investigational
FentanylThe serum concentration of Hydrocortisone can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FenthionThe therapeutic efficacy of Fenthion can be decreased when used in combination with Hydrocortisone.Vet Approved
FentiazacThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Feprazone.Experimental
FingolimodThe risk or severity of adverse effects can be increased when Fingolimod is combined with Hydrocortisone.Approved, Investigational
FirocoxibThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Firocoxib.Experimental, Vet Approved
FleroxacinThe risk or severity of tendinopathy can be increased when Hydrocortisone is combined with Fleroxacin.Approved
FloctafenineThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Floctafenine.Approved, Withdrawn
FloxuridineThe risk or severity of adverse effects can be increased when Floxuridine is combined with Hydrocortisone.Approved
FluasteroneThe risk or severity of edema formation can be increased when Fluasterone is combined with Hydrocortisone.Investigational
FlucloroloneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Fluclorolone.Experimental
FluconazoleThe serum concentration of Hydrocortisone can be increased when it is combined with Fluconazole.Approved, Investigational
FlucytosineThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Flucytosine.Approved, Investigational
FludarabineThe risk or severity of adverse effects can be increased when Fludarabine is combined with Hydrocortisone.Approved
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Hydrocortisone.Approved, Investigational
FlumequineThe risk or severity of tendinopathy can be increased when Hydrocortisone is combined with Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Fluocinonide.Approved, Investigational
FluocortinThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Fluocortin.Experimental
FluocortoloneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Fluorometholone.Approved, Investigational
FluorouracilThe risk or severity of adverse effects can be increased when Fluorouracil is combined with Hydrocortisone.Approved
FluoxetineThe serum concentration of Hydrocortisone can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FluoxymesteroneThe risk or severity of fluid retention can be increased when Hydrocortisone is combined with Fluoxymesterone.Approved, Illicit
FlupentixolThe serum concentration of Hydrocortisone can be increased when it is combined with Flupentixol.Approved, Investigational, Withdrawn
FluperoloneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Fluperolone.Experimental
FluphenazineThe serum concentration of Hydrocortisone can be increased when it is combined with Fluphenazine.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Fluprednisolone.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Flurandrenolide.Approved
FlurazepamThe serum concentration of Hydrocortisone can be increased when it is combined with Flurazepam.Approved, Illicit, Investigational
FlurbiprofenThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Flurbiprofen.Approved, Investigational
FluticasoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Fluticasone.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Fluticasone propionate.Approved
FluvoxamineThe serum concentration of Hydrocortisone can be increased when it is combined with Fluvoxamine.Approved, Investigational
FormestaneThe risk or severity of edema formation can be increased when Formestane is combined with Hydrocortisone.Approved, Investigational, Withdrawn
FormocortalThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Formocortal.Experimental
FormoterolThe risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Formoterol.Approved, Investigational
FosamprenavirThe metabolism of Hydrocortisone can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Hydrocortisone can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Hydrocortisone can be decreased when it is combined with Fosphenytoin.Approved, Investigational
FurosemideThe excretion of Hydrocortisone can be decreased when combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Hydrocortisone can be increased when it is combined with Fusidic Acid.Approved, Investigational
G17DTThe therapeutic efficacy of G17DT can be decreased when used in combination with Hydrocortisone.Investigational
GalantamineThe therapeutic efficacy of Galantamine can be decreased when used in combination with Hydrocortisone.Approved
GallamineThe risk or severity of myopathy and weakness can be increased when Gallamine is combined with Hydrocortisone.Experimental
Gallamine TriethiodideThe risk or severity of myopathy and weakness can be increased when Gallamine Triethiodide is combined with Hydrocortisone.Approved
Gallium nitrateThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Gallium nitrate.Approved, Investigational
GallopamilThe serum concentration of Hydrocortisone can be increased when it is combined with Gallopamil.Investigational
GarenoxacinThe risk or severity of tendinopathy can be increased when Hydrocortisone is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of tendinopathy can be increased when Hydrocortisone is combined with Gatifloxacin.Approved, Investigational
GefitinibThe serum concentration of Hydrocortisone can be increased when it is combined with Gefitinib.Approved, Investigational
GemcitabineThe risk or severity of adverse effects can be increased when Gemcitabine is combined with Hydrocortisone.Approved
GemifloxacinThe risk or severity of tendinopathy can be increased when Hydrocortisone is combined with Gemifloxacin.Approved, Investigational
GemigliptinThe therapeutic efficacy of Gemigliptin can be decreased when used in combination with Hydrocortisone.Investigational
Gemtuzumab ozogamicinThe risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Hydrocortisone.Approved, Investigational
GenisteinThe serum concentration of Hydrocortisone can be increased when it is combined with Genistein.Investigational
GestodeneThe serum concentration of Hydrocortisone can be increased when it is combined with Gestodene.Approved, Investigational
GI-5005The therapeutic efficacy of GI-5005 can be decreased when used in combination with Hydrocortisone.Investigational
Ginkgo bilobaThe therapeutic efficacy of Ginkgo biloba can be decreased when used in combination with Hydrocortisone.Approved, Investigational, Nutraceutical
GlatiramerThe risk or severity of adverse effects can be increased when Glatiramer is combined with Hydrocortisone.Approved, Investigational
GlecaprevirThe serum concentration of Hydrocortisone can be increased when it is combined with Glecaprevir.Approved, Investigational
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Hydrocortisone.Investigational, Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Hydrocortisone.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Hydrocortisone.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Hydrocortisone.Approved, Investigational
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Hydrocortisone.Approved, Investigational
GlisoxepideThe therapeutic efficacy of Glisoxepide can be decreased when used in combination with Hydrocortisone.Investigational
GLPG-0492The risk or severity of fluid retention can be increased when Hydrocortisone is combined with GLPG-0492.Investigational
GlyburideThe serum concentration of Hydrocortisone can be increased when it is combined with Glyburide.Approved
GlycerinThe serum concentration of Hydrocortisone can be increased when it is combined with Glycerin.Approved, Investigational
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Hydrocortisone.Approved
GlycodiazineThe therapeutic efficacy of Glycodiazine can be decreased when used in combination with Hydrocortisone.Approved, Investigational
GolimumabThe risk or severity of adverse effects can be increased when Golimumab is combined with Hydrocortisone.Approved
GosogliptinThe therapeutic efficacy of Gosogliptin can be decreased when used in combination with Hydrocortisone.Investigational
Gramicidin DThe serum concentration of Hydrocortisone can be increased when it is combined with Gramicidin D.Approved
GrepafloxacinThe risk or severity of tendinopathy can be increased when Hydrocortisone is combined with Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Hydrocortisone.Experimental
Guar gumThe therapeutic efficacy of Guar gum can be decreased when used in combination with Hydrocortisone.Experimental
GusperimusThe risk or severity of adverse effects can be increased when Gusperimus is combined with Hydrocortisone.Investigational
HalcinonideThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Halcinonide.Approved, Investigational, Withdrawn
HalometasoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Halometasone.Experimental
Hepatitis A VaccineThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Hydrocortisone.Approved
Hepatitis B Vaccine (Recombinant)The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Hydrocortisone.Approved, Withdrawn
HexoprenalineThe risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Hexoprenaline.Approved, Withdrawn
HM-30181The serum concentration of Hydrocortisone can be increased when it is combined with HM-30181.Experimental
Human rabies virus immune globulinThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Hydrocortisone.Approved
Huperzine AThe therapeutic efficacy of Huperzine A can be decreased when used in combination with Hydrocortisone.Approved, Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Hydrocortisone.Approved, Investigational
HycanthoneThe serum concentration of Hydrocortisone can be increased when it is combined with Hycanthone.Approved, Investigational
HydrochlorothiazideHydrocortisone may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe metabolism of Hydrocodone can be decreased when combined with Hydrocortisone.Approved, Illicit
Hydrocortisone aceponateThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Hydrocortisone aceponate.Experimental, Vet Approved
Hydrocortisone acetateThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Hydrocortisone acetate.Approved, Vet Approved
Hydrocortisone butyrateThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Hydrocortisone butyrate.Approved, Vet Approved
Hydrocortisone probutateThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Hydrocortisone probutate.Approved, Vet Approved
Hydrocortisone succinateThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Hydrocortisone succinate.Approved
Hydrocortisone valerateThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Hydrocortisone valerate.Approved, Vet Approved
HydroflumethiazideHydrocortisone may increase the hypokalemic activities of Hydroflumethiazide.Approved, Investigational
HydrotalciteThe bioavailability of Hydrocortisone can be decreased when combined with Hydrotalcite.Approved, Experimental, Investigational
HydroxychloroquineThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Hydroxychloroquine.Approved
HydroxyureaThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Hydroxyurea.Approved
HypericinThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Hypericin.Investigational
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Hydrocortisone.Approved, Investigational
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Hydrocortisone.Approved
IbuprofenThe serum concentration of Hydrocortisone can be increased when it is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Ibuproxam.Withdrawn
IcosapentThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Icosapent.Approved, Nutraceutical
IdarubicinThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Idarubicin.Approved
IdelalisibThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Idelalisib.Approved
IfosfamideThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Ifosfamide.Approved
ImatinibThe risk or severity of adverse effects can be increased when Imatinib is combined with Hydrocortisone.Approved
Imidazole salicylateThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Imidazole salicylate.Experimental
ImiquimodThe risk or severity of adverse effects can be increased when Imiquimod is combined with Hydrocortisone.Approved, Investigational
IndacaterolThe risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Indacaterol.Approved
IndapamideHydrocortisone may increase the hypokalemic activities of Indapamide.Approved
IndinavirThe metabolism of Hydrocortisone can be decreased when combined with Indinavir.Approved
IndobufenThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Indobufen.Investigational
IndomethacinThe serum concentration of Hydrocortisone can be increased when it is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Indoprofen.Withdrawn
InecalcitolThe therapeutic efficacy of Inecalcitol can be decreased when used in combination with Hydrocortisone.Experimental, Investigational
InfliximabThe risk or severity of adverse effects can be increased when Infliximab is combined with Hydrocortisone.Approved
INGN 225The therapeutic efficacy of INGN 225 can be decreased when used in combination with Hydrocortisone.Investigational
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Hydrocortisone.Approved
Insulin BeefThe therapeutic efficacy of Insulin Beef can be decreased when used in combination with Hydrocortisone.Approved
Insulin DegludecThe therapeutic efficacy of Insulin Degludec can be decreased when used in combination with Hydrocortisone.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Hydrocortisone.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Hydrocortisone.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Hydrocortisone.Approved
Insulin HumanThe therapeutic efficacy of Insulin Human can be decreased when used in combination with Hydrocortisone.Approved, Investigational
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Hydrocortisone.Approved
Insulin peglisproThe therapeutic efficacy of Insulin peglispro can be decreased when used in combination with Hydrocortisone.Investigational
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Hydrocortisone.Approved
Interferon alfa-n3The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Interferon alfa-n3.Approved, Investigational
Interferon alfacon-1The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Interferon alfacon-1.Approved, Investigational
IpidacrineThe therapeutic efficacy of Ipidacrine can be decreased when used in combination with Hydrocortisone.Experimental
IrinotecanThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Irinotecan.Approved, Investigational
IsavuconazoleThe serum concentration of Hydrocortisone can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe serum concentration of Hydrocortisone can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsoetarineThe risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Isoetarine.Approved
IsoflurophateThe therapeutic efficacy of Isoflurophate can be decreased when used in combination with Hydrocortisone.Approved, Investigational, Withdrawn
IsoniazidThe therapeutic efficacy of Isoniazid can be decreased when used in combination with Hydrocortisone.Approved, Investigational
IsoprenalineThe risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Isoprenaline.Approved, Investigational
IsoxicamThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Isoxicam.Withdrawn
IsradipineThe serum concentration of Hydrocortisone can be increased when it is combined with Isradipine.Approved, Investigational
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Hydrocortisone.Investigational
ItraconazoleThe metabolism of Hydrocortisone can be decreased when combined with Itraconazole.Approved, Investigational
IvermectinThe serum concentration of Hydrocortisone can be increased when it is combined with Ivermectin.Approved, Investigational, Vet Approved
IvosidenibThe serum concentration of Hydrocortisone can be increased when it is combined with Ivosidenib.Approved, Investigational
IxabepiloneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Ixabepilone.Approved, Investigational
Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Hydrocortisone.Approved
KebuzoneThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Kebuzone.Experimental
KetoconazoleThe metabolism of Hydrocortisone can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Ketorolac.Approved
KRP-104The therapeutic efficacy of KRP-104 can be decreased when used in combination with Hydrocortisone.Investigational
L-PhenylalanineThe risk or severity of adverse effects can be increased when L-Phenylalanine is combined with Hydrocortisone.Approved, Investigational, Nutraceutical
LaniquidarThe serum concentration of Hydrocortisone can be increased when it is combined with Laniquidar.Investigational
LansoprazoleThe serum concentration of Hydrocortisone can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Hydrocortisone can be increased when it is combined with Lapatinib.Approved, Investigational
LedipasvirThe serum concentration of Hydrocortisone can be increased when it is combined with Ledipasvir.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Hydrocortisone.Approved, Investigational
LenalidomideThe risk or severity of adverse effects can be increased when Lenalidomide is combined with Hydrocortisone.Approved
LetermovirThe serum concentration of Hydrocortisone can be increased when it is combined with Letermovir.Approved, Investigational
LevofloxacinThe serum concentration of Hydrocortisone can be increased when it is combined with Levofloxacin.Approved, Investigational
LevonorgestrelThe serum concentration of Hydrocortisone can be increased when it is combined with Levonorgestrel.Approved, Investigational
LevosalbutamolThe risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Levosalbutamol.Approved, Investigational
LidocaineThe serum concentration of Hydrocortisone can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Hydrocortisone can be increased when it is combined with Linagliptin.Approved
LinezolidThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Linezolid.Approved, Investigational
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Hydrocortisone.Approved
LisurideThe metabolism of Lisuride can be decreased when combined with Hydrocortisone.Approved, Investigational
LixisenatideThe therapeutic efficacy of Lixisenatide can be decreased when used in combination with Hydrocortisone.Approved
LobeglitazoneThe therapeutic efficacy of Lobeglitazone can be decreased when used in combination with Hydrocortisone.Approved, Investigational
LomefloxacinThe risk or severity of tendinopathy can be increased when Hydrocortisone is combined with Lomefloxacin.Approved, Investigational
LomerizineThe serum concentration of Hydrocortisone can be increased when it is combined with Lomerizine.Experimental
LomitapideThe serum concentration of Hydrocortisone can be increased when it is combined with Lomitapide.Approved, Investigational
LomustineThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Lomustine.Approved, Investigational
LonafarnibThe serum concentration of Hydrocortisone can be increased when it is combined with Lonafarnib.Investigational
LonazolacThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Lonazolac.Experimental
LoperamideThe serum concentration of Hydrocortisone can be increased when it is combined with Loperamide.Approved
LopinavirThe metabolism of Hydrocortisone can be decreased when combined with Lopinavir.Approved
LoratadineThe serum concentration of Hydrocortisone can be increased when it is combined with Loratadine.Approved, Investigational
LornoxicamThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Lornoxicam.Approved, Investigational
LorpiprazoleThe serum concentration of Hydrocortisone can be increased when it is combined with Lorpiprazole.Approved
LosartanThe serum concentration of Hydrocortisone can be increased when it is combined with Losartan.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Loteprednol.Approved
LovastatinThe serum concentration of Hydrocortisone can be increased when it is combined with Lovastatin.Approved, Investigational
LoxapineThe serum concentration of Hydrocortisone can be increased when it is combined with Loxapine.Approved
LoxoprofenThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Loxoprofen.Approved, Investigational
LuliconazoleThe serum concentration of Hydrocortisone can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Hydrocortisone can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Lumiracoxib.Approved, Investigational
LynestrenolThe serum concentration of Hydrocortisone can be increased when it is combined with Lynestrenol.Approved, Investigational
Lysergic Acid DiethylamideThe metabolism of Lysergic Acid Diethylamide can be decreased when combined with Hydrocortisone.Illicit, Investigational, Withdrawn
MagaldrateThe bioavailability of Hydrocortisone can be decreased when combined with Magaldrate.Approved, Withdrawn
Magnesium carbonateThe bioavailability of Hydrocortisone can be decreased when combined with Magnesium carbonate.Approved, Investigational
Magnesium hydroxideThe bioavailability of Hydrocortisone can be decreased when combined with Magnesium hydroxide.Approved, Investigational
Magnesium oxideThe bioavailability of Hydrocortisone can be decreased when combined with Magnesium oxide.Approved
Magnesium peroxideThe bioavailability of Hydrocortisone can be decreased when combined with Magnesium peroxide.Experimental
Magnesium salicylateThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Magnesium salicylate.Approved
Magnesium silicateThe bioavailability of Hydrocortisone can be decreased when combined with Magnesium silicate.Approved
Magnesium TrisilicateThe bioavailability of Hydrocortisone can be decreased when combined with Magnesium Trisilicate.Approved
MalathionThe therapeutic efficacy of Malathion can be decreased when used in combination with Hydrocortisone.Approved, Investigational
MaxacalcitolThe therapeutic efficacy of Maxacalcitol can be decreased when used in combination with Hydrocortisone.Approved, Investigational
MecaserminThe therapeutic efficacy of Mecasermin can be decreased when used in combination with Hydrocortisone.Approved, Investigational
MechlorethamineThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Mechlorethamine.Approved, Investigational
Meclofenamic acidThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Meclofenamic acid.Approved, Vet Approved
Medroxyprogesterone acetateThe serum concentration of Hydrocortisone can be increased when it is combined with Medroxyprogesterone acetate.Approved, Investigational
MedrysoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Mefenamic acid.Approved
MefloquineThe serum concentration of Hydrocortisone can be increased when it is combined with Mefloquine.Approved, Investigational
Megestrol acetateThe serum concentration of Hydrocortisone can be increased when it is combined with Megestrol acetate.Approved, Investigational, Vet Approved
MelengestrolThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Meloxicam.Approved, Vet Approved
MelphalanThe risk or severity of adverse effects can be increased when Melphalan is combined with Hydrocortisone.Approved
MepolizumabThe risk or severity of adverse effects can be increased when Mepolizumab is combined with Hydrocortisone.Approved, Investigational
MeprednisoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Meprednisone.Approved, Investigational
MercaptopurineThe risk or severity of adverse effects can be increased when Mercaptopurine is combined with Hydrocortisone.Approved
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Hydrocortisone.Approved
MesteroloneThe risk or severity of edema formation can be increased when Mesterolone is combined with Hydrocortisone.Experimental
MetahexamideThe therapeutic efficacy of Metahexamide can be decreased when used in combination with Hydrocortisone.Experimental
MetamizoleThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Metamizole.Approved, Investigational, Withdrawn
MetenoloneThe risk or severity of edema formation can be increased when Metenolone is combined with Hydrocortisone.Experimental
MetergolineThe metabolism of Metergoline can be decreased when combined with Hydrocortisone.Experimental
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Hydrocortisone.Approved
MethadoneThe serum concentration of Hydrocortisone can be increased when it is combined with Methadone.Approved
Methanesulfonyl FluorideThe therapeutic efficacy of Methanesulfonyl Fluoride can be decreased when used in combination with Hydrocortisone.Investigational
MethimazoleThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Methimazole.Approved
MethotrexateThe risk or severity of adverse effects can be increased when Methotrexate is combined with Hydrocortisone.Approved
MethyclothiazideHydrocortisone may increase the hypokalemic activities of Methyclothiazide.Approved
Methyl salicylateThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Hydrocortisone.Approved, Vet Approved
MethylergometrineThe metabolism of Methylergometrine can be decreased when combined with Hydrocortisone.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Methylprednisolone.Approved, Vet Approved
MethyltestosteroneThe risk or severity of edema formation can be increased when Methyltestosterone is combined with Hydrocortisone.Approved
MethysergideThe metabolism of Methysergide can be decreased when combined with Hydrocortisone.Approved
MetoclopramideThe therapeutic efficacy of Metoclopramide can be decreased when used in combination with Hydrocortisone.Approved, Investigational
MetocurineThe risk or severity of myopathy and weakness can be increased when Metocurine is combined with Hydrocortisone.Approved
Metocurine IodideThe risk or severity of myopathy and weakness can be increased when Metocurine Iodide is combined with Hydrocortisone.Approved, Withdrawn
MetolazoneHydrocortisone may increase the hypokalemic activities of Metolazone.Approved
MetronidazoleThe serum concentration of Hydrocortisone can be increased when it is combined with Metronidazole.Approved
MibefradilThe metabolism of Hydrocortisone can be decreased when combined with Mibefradil.Investigational, Withdrawn
MiboleroneThe risk or severity of edema formation can be increased when Mibolerone is combined with Hydrocortisone.Vet Approved
MiconazoleThe serum concentration of Hydrocortisone can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Hydrocortisone can be increased when it is combined with Midazolam.Approved, Illicit
MifamurtideThe therapeutic efficacy of Mifamurtide can be decreased when used in combination with Hydrocortisone.Approved, Experimental
MifepristoneThe serum concentration of Hydrocortisone can be increased when it is combined with Mifepristone.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Hydrocortisone.Approved
MinaprineThe therapeutic efficacy of Minaprine can be decreased when used in combination with Hydrocortisone.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Hydrocortisone.Approved, Investigational
MitomycinThe risk or severity of adverse effects can be increased when Mitomycin is combined with Hydrocortisone.Approved
MitotaneThe serum concentration of Hydrocortisone can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Mitoxantrone.Approved, Investigational
MivacuriumThe risk or severity of myopathy and weakness can be increased when Mivacurium is combined with Hydrocortisone.Approved
MizoribineThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Mizoribine.Investigational
ModafinilThe serum concentration of Hydrocortisone can be decreased when it is combined with Modafinil.Approved, Investigational
MofebutazoneThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Mofebutazone.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Mometasone.Approved, Vet Approved
Mometasone furoateThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Mometasone furoate.Approved, Vet Approved
MonensinThe serum concentration of Hydrocortisone can be increased when it is combined with Monensin.Vet Approved
MorniflumateThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Morniflumate.Approved
MoxifloxacinThe risk or severity of tendinopathy can be increased when Hydrocortisone is combined with Moxifloxacin.Approved, Investigational
MuromonabThe risk or severity of adverse effects can be increased when Muromonab is combined with Hydrocortisone.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Hydrocortisone.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Hydrocortisone.Approved
NabumetoneThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Nabumetone.Approved
NafcillinThe serum concentration of Hydrocortisone can be decreased when it is combined with Nafcillin.Approved, Investigational
Nalidixic AcidThe risk or severity of tendinopathy can be increased when Hydrocortisone is combined with Nalidixic Acid.Approved, Investigational
NaloxoneThe metabolism of Hydrocortisone can be decreased when combined with Naloxone.Approved, Vet Approved
NandroloneThe risk or severity of edema formation can be increased when Nandrolone is combined with Hydrocortisone.Experimental, Investigational
Nandrolone decanoateThe risk or severity of edema formation can be increased when Nandrolone decanoate is combined with Hydrocortisone.Approved, Illicit
Nandrolone phenpropionateThe risk or severity of edema formation can be increased when Nandrolone phenpropionate is combined with Hydrocortisone.Approved, Illicit, Investigational
NaproxenThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Naproxen.Approved, Vet Approved
NatalizumabThe risk or severity of adverse effects can be increased when Natalizumab is combined with Hydrocortisone.Approved, Investigational
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Hydrocortisone.Approved, Investigational
NBI-6024The therapeutic efficacy of NBI-6024 can be decreased when used in combination with Hydrocortisone.Investigational
NefazodoneThe metabolism of Hydrocortisone can be decreased when combined with Nefazodone.Approved, Withdrawn
NelarabineThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Nelarabine.Approved, Investigational
NelfinavirThe metabolism of Hydrocortisone can be decreased when combined with Nelfinavir.Approved
NemonoxacinThe risk or severity of tendinopathy can be increased when Hydrocortisone is combined with Nemonoxacin.Investigational
NeosaxitoxinThe risk or severity of myopathy and weakness can be increased when Neosaxitoxin is combined with Hydrocortisone.Investigational
NeostigmineThe therapeutic efficacy of Neostigmine can be decreased when used in combination with Hydrocortisone.Approved, Vet Approved
NepafenacThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Nepafenac.Approved, Investigational
NeratinibThe serum concentration of Hydrocortisone can be increased when it is combined with Neratinib.Approved, Investigational
NetoglitazoneThe therapeutic efficacy of Netoglitazone can be decreased when used in combination with Hydrocortisone.Experimental
NetupitantThe serum concentration of Hydrocortisone can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe serum concentration of Hydrocortisone can be decreased when it is combined with Nevirapine.Approved
NicardipineThe serum concentration of Hydrocortisone can be increased when it is combined with Nicardipine.Approved, Investigational
NicergolineThe metabolism of Nicergoline can be decreased when combined with Hydrocortisone.Approved, Investigational
NicorandilThe risk or severity of ulceration can be increased when Hydrocortisone is combined with Nicorandil.Approved, Investigational
NifenazoneThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Niflumic Acid.Approved
NigericinThe serum concentration of Hydrocortisone can be increased when it is combined with Nigericin.Experimental
NiguldipineThe serum concentration of Hydrocortisone can be increased when it is combined with Niguldipine.Experimental
NilotinibThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Nilotinib.Approved, Investigational
NimesulideThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe serum concentration of Nimodipine can be decreased when it is combined with Hydrocortisone.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be decreased when it is combined with Hydrocortisone.Approved
NisoldipineThe serum concentration of Hydrocortisone can be increased when it is combined with Nisoldipine.Approved
NitrendipineThe serum concentration of Hydrocortisone can be increased when it is combined with Nitrendipine.Approved, Investigational
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Hydrocortisone.Investigational
NN344The therapeutic efficacy of NN344 can be decreased when used in combination with Hydrocortisone.Investigational
NomegestrolThe serum concentration of Hydrocortisone can be increased when it is combined with Nomegestrol.Approved
NorelgestrominThe serum concentration of Hydrocortisone can be increased when it is combined with Norelgestromin.Approved, Investigational
NorepinephrineThe risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Norepinephrine.Approved
NorethisteroneThe serum concentration of Hydrocortisone can be increased when it is combined with Norethisterone.Approved
NorfloxacinThe risk or severity of tendinopathy can be increased when Hydrocortisone is combined with Norfloxacin.Approved
NorgestimateThe serum concentration of Hydrocortisone can be increased when it is combined with Norgestimate.Approved, Investigational
NorgestrelThe serum concentration of Hydrocortisone can be increased when it is combined with Norgestrel.Approved
NorgestrienoneThe serum concentration of Hydrocortisone can be increased when it is combined with Norgestrienone.Experimental
NS-398The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with NS-398.Experimental
ObinutuzumabThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Obinutuzumab.Approved, Investigational
OcrelizumabThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Ocrelizumab.Approved, Investigational
OfloxacinThe risk or severity of tendinopathy can be increased when Hydrocortisone is combined with Ofloxacin.Approved
OlaparibThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Olaparib.Approved
OlodaterolThe risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Olodaterol.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Hydrocortisone.Approved
OmarigliptinThe therapeutic efficacy of Omarigliptin can be decreased when used in combination with Hydrocortisone.Investigational
OmeprazoleThe serum concentration of Hydrocortisone can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
ONT-093The serum concentration of Hydrocortisone can be increased when it is combined with ONT-093.Investigational
OrbifloxacinThe risk or severity of tendinopathy can be increased when Hydrocortisone is combined with Orbifloxacin.Vet Approved
OrciprenalineThe risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Orciprenaline.Approved
OsimertinibThe serum concentration of Hydrocortisone can be increased when it is combined with Osimertinib.Approved
OxaliplatinThe risk or severity of adverse effects can be increased when Oxaliplatin is combined with Hydrocortisone.Approved, Investigational
OxandroloneThe risk or severity of fluid retention can be increased when Hydrocortisone is combined with Oxandrolone.Approved, Investigational
OxaprozinThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Oxaprozin.Approved
Oxolinic acidThe risk or severity of tendinopathy can be increased when Hydrocortisone is combined with Oxolinic acid.Experimental
OxymetholoneThe risk or severity of fluid retention can be increased when Hydrocortisone is combined with Oxymetholone.Approved, Illicit
OxyphenbutazoneThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Oxyphenbutazone.Approved, Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Hydrocortisone can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidoneThe serum concentration of Hydrocortisone can be increased when it is combined with Paliperidone.Approved
PancuroniumThe risk or severity of myopathy and weakness can be increased when Pancuronium is combined with Hydrocortisone.Approved
PanobinostatThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Panobinostat.Approved, Investigational
PantoprazoleThe serum concentration of Hydrocortisone can be increased when it is combined with Pantoprazole.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Paramethasone.Approved
ParaoxonThe therapeutic efficacy of Paraoxon can be decreased when used in combination with Hydrocortisone.Experimental
ParecoxibThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Parecoxib.Approved
ParicalcitolThe therapeutic efficacy of Paricalcitol can be decreased when used in combination with Hydrocortisone.Approved, Investigational
ParitaprevirThe serum concentration of Hydrocortisone can be increased when it is combined with Paritaprevir.Approved, Investigational
ParoxetineThe serum concentration of Hydrocortisone can be increased when it is combined with Paroxetine.Approved, Investigational
PazopanibThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Pazopanib.Approved
PazufloxacinThe risk or severity of tendinopathy can be increased when Hydrocortisone is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of tendinopathy can be increased when Hydrocortisone is combined with Pefloxacin.Approved
PegaspargaseThe risk or severity of adverse effects can be increased when Pegaspargase is combined with Hydrocortisone.Approved, Investigational
Peginterferon alfa-2aThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Peginterferon alfa-2a.Approved, Investigational
Peginterferon alfa-2bThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Peginterferon alfa-2b.Approved
PemetrexedThe risk or severity of adverse effects can be increased when Pemetrexed is combined with Hydrocortisone.Approved, Investigational
PentamidineThe therapeutic efficacy of Pentamidine can be decreased when used in combination with Hydrocortisone.Approved, Investigational
PentazocineThe serum concentration of Hydrocortisone can be increased when it is combined with Pentazocine.Approved, Vet Approved
PentobarbitalThe serum concentration of Hydrocortisone can be decreased when it is combined with Pentobarbital.Approved, Investigational, Vet Approved
PentostatinThe risk or severity of adverse effects can be increased when Pentostatin is combined with Hydrocortisone.Approved, Investigational
PergolideThe metabolism of Pergolide can be decreased when combined with Hydrocortisone.Approved, Investigational, Vet Approved, Withdrawn
PethidineThe serum concentration of Hydrocortisone can be increased when it is combined with Pethidine.Approved
PF-00610355The risk or severity of hypokalemia can be increased when Hydrocortisone is combined with PF-00610355.Investigational
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Hydrocortisone.Approved, Investigational, Withdrawn
PhenobarbitalThe serum concentration of Hydrocortisone can be decreased when it is combined with Phenobarbital.Approved, Investigational
Phenyl aminosalicylateThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Hydrocortisone.Approved
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Hydrocortisone.Approved
PhenylbutazoneThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Phenylbutazone.Approved, Vet Approved
Phenylbutyric acidThe therapeutic efficacy of Phenylbutyric acid can be decreased when used in combination with Hydrocortisone.Approved, Investigational
PhenylpropanolamineThe risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinThe serum concentration of Hydrocortisone can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe therapeutic efficacy of Physostigmine can be decreased when used in combination with Hydrocortisone.Approved, Investigational
PibrentasvirThe serum concentration of Hydrocortisone can be increased when it is combined with Pibrentasvir.Approved, Investigational
PimecrolimusThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Pimecrolimus.Approved, Investigational
PimozideThe serum concentration of Hydrocortisone can be increased when it is combined with Pimozide.Approved
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Hydrocortisone.Approved, Investigational
PipecuroniumThe risk or severity of myopathy and weakness can be increased when Pipecuronium is combined with Hydrocortisone.Approved
Pipemidic acidThe risk or severity of tendinopathy can be increased when Hydrocortisone is combined with Pipemidic acid.Experimental
PirarubicinThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Pirarubicin.Investigational
PirbuterolThe risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Pirbuterol.Approved
PiretanideThe risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Piretanide.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Pirfenidone.Approved, Investigational
Piromidic acidThe risk or severity of tendinopathy can be increased when Hydrocortisone is combined with Piromidic acid.Experimental
PiroxicamThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Piroxicam.Approved, Investigational
PirprofenThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Pirprofen.Experimental
PitolisantThe serum concentration of Hydrocortisone can be decreased when it is combined with Pitolisant.Approved, Investigational
PolythiazideHydrocortisone may increase the hypokalemic activities of Polythiazide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Hydrocortisone.Approved
PonatinibThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Ponatinib.Approved, Investigational
PosaconazoleThe metabolism of Hydrocortisone can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PralatrexateThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Pralatrexate.Approved, Investigational
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Hydrocortisone.Approved, Investigational
PranoprofenThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Pranoprofen.Experimental, Investigational
PrasteroneThe risk or severity of edema formation can be increased when Prasterone is combined with Hydrocortisone.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of edema formation can be increased when Prasterone sulfate is combined with Hydrocortisone.Investigational
PrazosinThe serum concentration of Hydrocortisone can be increased when it is combined with Prazosin.Approved
PrednicarbateThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Prednicarbate.Approved, Investigational
PrednisoloneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Hydrocortisone.Approved, Vet Approved
PrednylideneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Prednylidene.Experimental
PrimaquineThe serum concentration of Hydrocortisone can be increased when it is combined with Primaquine.Approved
PrimidoneThe serum concentration of Hydrocortisone can be decreased when it is combined with Primidone.Approved, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Procarbazine.Approved, Investigational
ProcaterolThe risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Procaterol.Approved, Investigational
ProgesteroneThe serum concentration of Hydrocortisone can be increased when it is combined with Progesterone.Approved, Vet Approved
ProglumetacinThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Proglumetacin.Experimental
PromethazineThe serum concentration of Hydrocortisone can be increased when it is combined with Promethazine.Approved, Investigational
PropacetamolThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Propacetamol.Approved, Investigational
PropafenoneThe serum concentration of Hydrocortisone can be increased when it is combined with Propafenone.Approved
PropofolThe serum concentration of Hydrocortisone can be increased when it is combined with Propofol.Approved, Investigational, Vet Approved
PropylthiouracilThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Propylthiouracil.Approved, Investigational
PropyphenazoneThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Proquazone.Experimental
ProtokylolThe risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Protokylol.Approved, Vet Approved
ProtriptylineThe serum concentration of Hydrocortisone can be increased when it is combined with Protriptyline.Approved
PrulifloxacinThe risk or severity of tendinopathy can be increased when Hydrocortisone is combined with Prulifloxacin.Investigational
PyrantelThe risk or severity of myopathy and weakness can be increased when Pyrantel is combined with Hydrocortisone.Approved, Vet Approved
PyridostigmineThe therapeutic efficacy of Pyridostigmine can be decreased when used in combination with Hydrocortisone.Approved, Investigational
QuercetinThe serum concentration of Hydrocortisone can be increased when it is combined with Quercetin.Experimental, Investigational
QuinacrineThe serum concentration of Hydrocortisone can be increased when it is combined with Quinacrine.Approved, Investigational
QuinethazoneHydrocortisone may increase the hypokalemic activities of Quinethazone.Approved
QuingestanolThe serum concentration of Hydrocortisone can be increased when it is combined with Quingestanol.Experimental
QuinidineThe serum concentration of Hydrocortisone can be increased when it is combined with Quinidine.Approved, Investigational
QuinineThe serum concentration of Hydrocortisone can be decreased when it is combined with Quinine.Approved
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Hydrocortisone.Approved, Investigational
RacepinephrineThe risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Racepinephrine.Approved
RaltitrexedThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Raltitrexed.Approved, Investigational
RanitidineThe serum concentration of Hydrocortisone can be increased when it is combined with Ranitidine.Approved
RapacuroniumThe risk or severity of myopathy and weakness can be increased when Rapacuronium is combined with Hydrocortisone.Withdrawn
ReboxetineThe serum concentration of Hydrocortisone can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Hydrocortisone can be increased when it is combined with Regorafenib.Approved
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Hydrocortisone.Approved, Investigational
ReserpineThe serum concentration of Hydrocortisone can be increased when it is combined with Reserpine.Approved, Investigational
Reversin 121The serum concentration of Hydrocortisone can be increased when it is combined with Reversin 121.Experimental
RifampicinThe serum concentration of Hydrocortisone can be decreased when it is combined with Rifampicin.Approved
RifamycinThe serum concentration of Hydrocortisone can be decreased when it is combined with Rifamycin.Investigational
RifapentineThe serum concentration of Hydrocortisone can be decreased when it is combined with Rifapentine.Approved, Investigational
RifaximinThe serum concentration of Hydrocortisone can be decreased when it is combined with Rifaximin.Approved, Investigational
RilonaceptThe risk or severity of adverse effects can be increased when Rilonacept is combined with Hydrocortisone.Approved, Investigational
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Hydrocortisone.Approved
RimexoloneThe serum concentration of Hydrocortisone can be decreased when it is combined with Rimexolone.Approved
RindopepimutThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Hydrocortisone.Investigational
RisperidoneThe metabolism of Hydrocortisone can be decreased when combined with Risperidone.Approved, Investigational
RitodrineThe risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Ritodrine.Approved, Investigational
RitonavirThe metabolism of Hydrocortisone can be decreased when combined with Ritonavir.Approved, Investigational
RituximabThe risk or severity of adverse effects can be increased when Rituximab is combined with Hydrocortisone.Approved
RivastigmineThe therapeutic efficacy of Rivastigmine can be decreased when used in combination with Hydrocortisone.Approved, Investigational
RivoglitazoneThe therapeutic efficacy of Rivoglitazone can be decreased when used in combination with Hydrocortisone.Experimental, Investigational
RobenacoxibThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Robenacoxib.Experimental, Vet Approved
RocuroniumThe risk or severity of myopathy and weakness can be increased when Rocuronium is combined with Hydrocortisone.Approved
RofecoxibThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Rofecoxib.Approved, Investigational, Withdrawn
RoflumilastRoflumilast may increase the immunosuppressive activities of Hydrocortisone.Approved
RolapitantThe serum concentration of Hydrocortisone can be increased when it is combined with Rolapitant.Approved, Investigational
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Hydrocortisone.Approved, Investigational
RosoxacinThe risk or severity of tendinopathy can be increased when Hydrocortisone is combined with Rosoxacin.Approved, Investigational
Rotavirus VaccineThe therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Hydrocortisone.Approved
Rubella virus vaccineThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Hydrocortisone.Approved, Investigational
RucaparibThe serum concentration of Hydrocortisone can be increased when it is combined with Rucaparib.Approved, Investigational
RufloxacinThe risk or severity of tendinopathy can be increased when Hydrocortisone is combined with Rufloxacin.Experimental
RuxolitinibThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Ruxolitinib.Approved
SalbutamolThe risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Salbutamol.Approved, Vet Approved
SalicylamideThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Hydrocortisone.Approved, Investigational, Vet Approved
SalinomycinThe serum concentration of Hydrocortisone can be increased when it is combined with Salinomycin.Vet Approved
SalmeterolThe risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Salmeterol.Approved
Salmonella typhi ty2 vi polysaccharide antigenThe therapeutic efficacy of Salmonella typhi ty2 vi polysaccharide antigen can be decreased when used in combination with Hydrocortisone.Approved
Salmonella typhi Ty21a live antigenThe risk or severity of infection can be increased when Salmonella typhi Ty21a live antigen is combined with Hydrocortisone.Approved
Salmonella typhi Ty21a live antigenThe therapeutic efficacy of Salmonella typhi Ty21a live antigen can be decreased when used in combination with Hydrocortisone.Approved
SalsalateThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Salsalate.Approved
SaquinavirThe metabolism of Hydrocortisone can be decreased when combined with Saquinavir.Approved, Investigational
SarafloxacinThe risk or severity of tendinopathy can be increased when Hydrocortisone is combined with Sarafloxacin.Vet Approved, Withdrawn
SarilumabThe therapeutic efficacy of Hydrocortisone can be decreased when used in combination with Sarilumab.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Hydrocortisone.Approved
SC-236The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with SC-236.Experimental, Investigational
SecukinumabThe risk or severity of adverse effects can be increased when Secukinumab is combined with Hydrocortisone.Approved
SemaglutideThe therapeutic efficacy of Semaglutide can be decreased when used in combination with Hydrocortisone.Approved, Investigational
SeocalcitolThe therapeutic efficacy of Seocalcitol can be decreased when used in combination with Hydrocortisone.Experimental, Investigational
SertralineThe serum concentration of Hydrocortisone can be increased when it is combined with Sertraline.Approved
SiltuximabThe serum concentration of Hydrocortisone can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Hydrocortisone can be increased when it is combined with Simeprevir.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Hydrocortisone.Approved, Investigational
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Hydrocortisone.Approved, Investigational
SitafloxacinThe risk or severity of tendinopathy can be increased when Hydrocortisone is combined with Sitafloxacin.Experimental, Investigational
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Hydrocortisone.Approved, Investigational
Sodium bicarbonateThe bioavailability of Hydrocortisone can be decreased when combined with Sodium bicarbonate.Approved
SorafenibThe risk or severity of adverse effects can be increased when Sorafenib is combined with Hydrocortisone.Approved, Investigational
SotagliflozinThe therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Hydrocortisone.Investigational
SparfloxacinThe risk or severity of tendinopathy can be increased when Hydrocortisone is combined with Sparfloxacin.Approved, Investigational
SRP 299The therapeutic efficacy of SRP 299 can be decreased when used in combination with Hydrocortisone.Investigational
St. John's WortThe serum concentration of Hydrocortisone can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StanoloneThe risk or severity of edema formation can be increased when Stanolone is combined with Hydrocortisone.Illicit, Investigational
StanozololThe risk or severity of fluid retention can be increased when Hydrocortisone is combined with Stanozolol.Approved, Vet Approved
StaurosporineThe serum concentration of Hydrocortisone can be increased when it is combined with Staurosporine.Experimental
SteproninThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Stepronin.Approved
StiripentolThe serum concentration of Hydrocortisone can be increased when it is combined with Stiripentol.Approved
StreptozocinThe risk or severity of adverse effects can be increased when Streptozocin is combined with Hydrocortisone.Approved, Investigational
SuccinylcholineThe risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Hydrocortisone.Approved
SulfadiazineThe therapeutic efficacy of Sulfadiazine can be decreased when used in combination with Hydrocortisone.Approved, Investigational, Vet Approved
SulfamethoxazoleThe therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Hydrocortisone.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Sulfasalazine.Approved
SulfisoxazoleThe therapeutic efficacy of Sulfisoxazole can be decreased when used in combination with Hydrocortisone.Approved, Vet Approved
SulindacThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Sulindac.Approved, Investigational
SunitinibThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Sunitinib.Approved, Investigational
SuprofenThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Suprofen.Approved, Withdrawn
SuvorexantThe serum concentration of Hydrocortisone can be increased when it is combined with Suvorexant.Approved, Investigational
SuxibuzoneThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Suxibuzone.Experimental
TacalcitolThe therapeutic efficacy of Tacalcitol can be decreased when used in combination with Hydrocortisone.Experimental, Investigational
TacrineThe therapeutic efficacy of Tacrine can be decreased when used in combination with Hydrocortisone.Investigational, Withdrawn
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Hydrocortisone.Approved, Investigational
TalniflumateThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Talniflumate.Approved
TamoxifenThe serum concentration of Hydrocortisone can be increased when it is combined with Tamoxifen.Approved
TariquidarThe serum concentration of Hydrocortisone can be increased when it is combined with Tariquidar.Investigational
TaspoglutideThe therapeutic efficacy of Taspoglutide can be decreased when used in combination with Hydrocortisone.Investigational
TecemotideThe therapeutic efficacy of Tecemotide can be decreased when used in combination with Hydrocortisone.Investigational
Technetium Tc-99m ciprofloxacinThe risk or severity of tendinopathy can be increased when Hydrocortisone is combined with Technetium Tc-99m ciprofloxacin.Investigational
Tedizolid phosphateThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Tedizolid phosphate.Approved
TelaprevirThe metabolism of Hydrocortisone can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Hydrocortisone can be decreased when combined with Telithromycin.Approved
TelmisartanThe serum concentration of Hydrocortisone can be increased when it is combined with Telmisartan.Approved, Investigational
TemafloxacinThe risk or severity of tendinopathy can be increased when Hydrocortisone is combined with Temafloxacin.Withdrawn
TemozolomideThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Temozolomide.Approved, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Temsirolimus.Approved
TeneligliptinThe therapeutic efficacy of Teneligliptin can be decreased when used in combination with Hydrocortisone.Investigational
TenidapThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Tenidap.Experimental
TeniposideThe risk or severity of adverse effects can be increased when Teniposide is combined with Hydrocortisone.Approved
TenoxicamThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Tepoxalin.Vet Approved
TerbutalineThe risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Terbutaline.Approved
TerfenadineThe serum concentration of Hydrocortisone can be increased when it is combined with Terfenadine.Approved, Withdrawn
TergurideThe metabolism of Terguride can be decreased when combined with Hydrocortisone.Experimental
TeriflunomideThe serum concentration of Hydrocortisone can be increased when it is combined with Teriflunomide.Approved
TesmilifeneThe serum concentration of Hydrocortisone can be increased when it is combined with Tesmilifene.Investigational
TestosteroneThe risk or severity of edema formation can be increased when Testosterone is combined with Hydrocortisone.Approved, Investigational
Testosterone cypionateThe risk or severity of edema formation can be increased when Testosterone cypionate is combined with Hydrocortisone.Approved
Testosterone enantate benzilic acid hydrazoneThe risk or severity of edema formation can be increased when Testosterone enantate benzilic acid hydrazone is combined with Hydrocortisone.Approved, Experimental
Testosterone enanthateThe risk or severity of edema formation can be increased when Testosterone enanthate is combined with Hydrocortisone.Approved
Testosterone propionateThe risk or severity of edema formation can be increased when Testosterone propionate is combined with Hydrocortisone.Approved, Investigational, Vet Approved, Withdrawn
Testosterone succinateThe risk or severity of edema formation can be increased when Testosterone succinate is combined with Hydrocortisone.Experimental
Testosterone undecanoateThe risk or severity of edema formation can be increased when Testosterone undecanoate is combined with Hydrocortisone.Approved, Investigational
TetracyclineThe excretion of Hydrocortisone can be decreased when combined with Tetracycline.Approved, Vet Approved
TetrandrineThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Tetrandrine.Experimental
TG4010The therapeutic efficacy of TG4010 can be decreased when used in combination with Hydrocortisone.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Hydrocortisone.Approved, Investigational, Withdrawn
ThiotepaThe risk or severity of adverse effects can be increased when Thiotepa is combined with Hydrocortisone.Approved, Investigational
Tiaprofenic acidThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Tiaprofenic acid.Approved
TicagrelorThe serum concentration of Hydrocortisone can be increased when it is combined with Ticagrelor.Approved
TinoridineThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Tinoridine.Investigational
TioguanineThe risk or severity of adverse effects can be increased when Tioguanine is combined with Hydrocortisone.Approved
TipifarnibThe serum concentration of Hydrocortisone can be increased when it is combined with Tipifarnib.Investigational
TipranavirThe metabolism of Hydrocortisone can be decreased when combined with Tipranavir.Approved, Investigational
TixocortolThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Tixocortol.Approved, Withdrawn
TocilizumabThe serum concentration of Hydrocortisone can be decreased when it is combined with Tocilizumab.Approved
TofacitinibThe risk or severity of adverse effects can be increased when Tofacitinib is combined with Hydrocortisone.Approved, Investigational
TofacitinibHydrocortisone may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Hydrocortisone.Approved, Investigational
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Hydrocortisone.Approved, Investigational
Tolfenamic AcidThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Tolfenamic Acid.Approved, Investigational
TolmetinThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Tolmetin.Approved
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Hydrocortisone.Approved
TopotecanThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Topotecan.Approved, Investigational
TorasemideThe risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Torasemide.Approved
ToremifeneThe serum concentration of Hydrocortisone can be increased when it is combined with Toremifene.Approved, Investigational
TositumomabThe risk or severity of adverse effects can be increased when Tositumomab is combined with Hydrocortisone.Approved, Investigational
TrabectedinThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Trabectedin.Approved, Investigational
TrastuzumabThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Trastuzumab.Approved, Investigational
Trastuzumab emtansineThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Trastuzumab emtansine.Approved, Investigational
TrestoloneThe risk or severity of edema formation can be increased when Trestolone is combined with Hydrocortisone.Investigational
Trestolone acetateThe risk or severity of edema formation can be increased when Trestolone acetate is combined with Hydrocortisone.Experimental
TretinoinThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Hydrocortisone.Approved, Vet Approved
TrichlorfonThe therapeutic efficacy of Trichlorfon can be decreased when used in combination with Hydrocortisone.Vet Approved
TrichlormethiazideHydrocortisone may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineThe serum concentration of Hydrocortisone can be increased when it is combined with Trifluoperazine.Approved, Investigational
TriflupromazineThe serum concentration of Hydrocortisone can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrifluridineThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Trifluridine.Approved, Investigational
TrilostaneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Trilostane.Approved, Investigational, Vet Approved, Withdrawn
TrimethoprimThe serum concentration of Hydrocortisone can be increased when it is combined with Trimethoprim.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Triptolide.Investigational
TrofosfamideThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Trofosfamide.Investigational
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Hydrocortisone.Investigational, Withdrawn
Trolamine salicylateThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Hydrocortisone.Approved
TroleandomycinThe metabolism of Hydrocortisone can be decreased when combined with Troleandomycin.Approved
TrovafloxacinThe risk or severity of tendinopathy can be increased when Hydrocortisone is combined with Trovafloxacin.Approved, Investigational, Withdrawn
TubocurarineThe risk or severity of myopathy and weakness can be increased when Tubocurarine is combined with Hydrocortisone.Approved
Typhoid VaccineThe therapeutic efficacy of Typhoid Vaccine can be decreased when used in combination with Hydrocortisone.Approved
TyrothricinThe therapeutic efficacy of Tyrothricin can be decreased when used in combination with Hydrocortisone.Approved
UlipristalThe serum concentration of Hydrocortisone can be increased when it is combined with Ulipristal.Approved
UlobetasolThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Ulobetasol.Approved
UstekinumabThe risk or severity of adverse effects can be increased when Ustekinumab is combined with Hydrocortisone.Approved, Investigational
ValdecoxibThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Valdecoxib.Approved, Investigational, Withdrawn
ValinomycinThe serum concentration of Hydrocortisone can be increased when it is combined with Valinomycin.Experimental
ValspodarThe serum concentration of Hydrocortisone can be increased when it is combined with Valspodar.Investigational
Varicella Zoster Vaccine (Live/Attenuated)The risk or severity of infection can be increased when Varicella Zoster Vaccine (Live/Attenuated) is combined with Hydrocortisone.Approved
Varicella Zoster Vaccine (Live/Attenuated)The therapeutic efficacy of Varicella Zoster Vaccine (Live/Attenuated) can be decreased when used in combination with Hydrocortisone.Approved
VecuroniumThe risk or severity of myopathy and weakness can be increased when Vecuronium is combined with Hydrocortisone.Approved
VedolizumabThe risk or severity of adverse effects can be increased when Vedolizumab is combined with Hydrocortisone.Approved
VelpatasvirThe serum concentration of Hydrocortisone can be increased when it is combined with Velpatasvir.Approved, Investigational
VemurafenibThe serum concentration of Hydrocortisone can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe serum concentration of Hydrocortisone can be increased when it is combined with Venlafaxine.Approved
VerapamilThe serum concentration of Hydrocortisone can be increased when it is combined with Verapamil.Approved
Vibrio cholerae CVD 103-HgR strain live antigenThe risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Hydrocortisone.Approved, Investigational
Vibrio cholerae CVD 103-HgR strain live antigenThe therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Hydrocortisone.Approved, Investigational
VilanterolThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Vilanterol.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Hydrocortisone.Approved, Investigational
VinblastineThe risk or severity of adverse effects can be increased when Vinblastine is combined with Hydrocortisone.Approved
VincristineThe risk or severity of adverse effects can be increased when Vincristine is combined with Hydrocortisone.Approved, Investigational
VindesineThe risk or severity of adverse effects can be increased when Vindesine is combined with Hydrocortisone.Approved, Investigational
VinorelbineThe risk or severity of adverse effects can be increased when Vinorelbine is combined with Hydrocortisone.Approved, Investigational
Vitamin DThe therapeutic efficacy of Vitamin D can be decreased when used in combination with Hydrocortisone.Approved, Nutraceutical, Vet Approved
VoacamineThe serum concentration of Hydrocortisone can be increased when it is combined with Voacamine.Approved, Investigational
VoclosporinThe risk or severity of adverse effects can be increased when Voclosporin is combined with Hydrocortisone.Investigational
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Hydrocortisone.Approved, Investigational
VorapaxarThe serum concentration of Hydrocortisone can be increased when it is combined with Vorapaxar.Approved
VoriconazoleThe metabolism of Hydrocortisone can be decreased when combined with Voriconazole.Approved, Investigational
VorinostatThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Vorinostat.Approved, Investigational
VoxilaprevirThe serum concentration of Hydrocortisone can be increased when it is combined with Voxilaprevir.Approved, Investigational
WarfarinThe therapeutic efficacy of Warfarin can be increased when used in combination with Hydrocortisone.Approved
WortmanninThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Wortmannin.Experimental
Yellow Fever VaccineThe risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Hydrocortisone.Approved, Investigational
Yellow Fever VaccineThe therapeutic efficacy of Yellow Fever Vaccine can be decreased when used in combination with Hydrocortisone.Approved, Investigational
YohimbineThe serum concentration of Hydrocortisone can be increased when it is combined with Yohimbine.Approved, Investigational, Vet Approved
ZaltoprofenThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Zaltoprofen.Approved, Investigational
ZidovudineThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Zidovudine.Approved
ZiprasidoneThe metabolism of Hydrocortisone can be decreased when combined with Ziprasidone.Approved
ZomepiracThe serum concentration of Hydrocortisone can be increased when it is combined with Zomepirac.Withdrawn
ZosuquidarThe serum concentration of Hydrocortisone can be increased when it is combined with Zosuquidar.Investigational
Food Interactions
  • Take with food to reduce irritation. Calcium, phosphorous, potassium, Vitamin A, C, D and zinc needs increased with long term use.

References

Synthesis Reference

Manfred Baumgarth, Dieter Orth, Jurgen Harting, Hans Schaefer, Achim Zesch, "Hydrocortisone orthoesters, pharmaceutical formulations thereof and processes for the preparation thereof." U.S. Patent US4264584, issued March, 1974.

US4264584
General References
  1. de Weerth C, Zijl RH, Buitelaar JK: Development of cortisol circadian rhythm in infancy. Early Hum Dev. 2003 Aug;73(1-2):39-52. [PubMed:12932892]
  2. Palacios R, Sugawara I: Hydrocortisone abrogates proliferation of T cells in autologous mixed lymphocyte reaction by rendering the interleukin-2 Producer T cells unresponsive to interleukin-1 and unable to synthesize the T-cell growth factor. Scand J Immunol. 1982 Jan;15(1):25-31. [PubMed:6461917]
  3. KNIGHT RP Jr, KORNFELD DS, GLASER GH, BONDY PK: Effects of intravenous hydrocortisone on electrolytes of serum and urine in man. J Clin Endocrinol Metab. 1955 Feb;15(2):176-81. [PubMed:13233328]
External Links
Human Metabolome Database
HMDB0000063
KEGG Drug
D00088
KEGG Compound
C00735
PubChem Compound
5754
PubChem Substance
46505089
ChemSpider
5551
BindingDB
13775
ChEBI
17650
ChEMBL
CHEMBL389621
Therapeutic Targets Database
DAP000718
PharmGKB
PA449905
IUPHAR
2868
Guide to Pharmacology
GtP Drug Page
HET
HCY
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Hydrocortisone
ATC Codes
S03CA04 — Hydrocortisone and antiinfectivesS01CB03 — HydrocortisoneS01CA03 — Hydrocortisone and antiinfectivesS02BA01 — HydrocortisoneS02CA03 — Hydrocortisone and antiinfectivesD07AA02 — HydrocortisoneC05AA01 — HydrocortisoneD07BA04 — Hydrocortisone and antisepticsA01AC03 — HydrocortisoneD07CA01 — Hydrocortisone and antibioticsS01BA02 — HydrocortisoneS01BB01 — Hydrocortisone and mydriaticsA07EA02 — HydrocortisoneR01AD60 — Hydrocortisone, combinationsH02AB09 — HydrocortisoneD07XA01 — Hydrocortisone
AHFS Codes
  • 68:04.00 — Adrenals
  • 84:06.00 — Anti-inflammatory Agents
  • 56:36.00 — Anti-inflammatory Agents
PDB Entries
2v95 / 2vdy / 4c49 / 4p6x / 5hgc
FDA label
Download (30 KB)
MSDS
Download (73.6 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Active Not RecruitingOtherInsulin Resistance1
0CompletedTreatmentFibromyalgia1
0RecruitingBasic ScienceDepression1
0RecruitingBasic ScienceHealthy Volunteers1
0RecruitingBasic ScienceHuman Immunodeficiency Virus (HIV)1
0WithdrawnBasic ScienceBMI >30 kg/m2 / Hyperandrogenemia / Polycystic Ovaries Syndrome2
1Active Not RecruitingBasic ScienceBMI >30 kg/m21
1Active Not RecruitingTreatmentRotator Cuff Tear - Partial Thickness1
1CompletedNot AvailableInfection NOS1
1CompletedNot AvailableRelative Adrenal Insufficiency / Sepsis1
1CompletedBasic ScienceHealthy Volunteers2
1CompletedBasic ScienceHealthy Volunteers / Inflammatory Reaction / Pain1
1CompletedOtherAdrenal Insufficiency1
1CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukemia Acute Myeloid Leukemia (AML) / Mixed Phenotype Acute Leukemia (MPAL) / Myelodysplastic Syndromes (MDS)1
1CompletedTreatmentAdrenal Insufficiency2
1CompletedTreatmentAdrenal Insufficiency / Congenital Adrenal Hyperplasia (CAH)1
1CompletedTreatmentArterial Hypotension / Blood Pressures / Infant, Low Birth Weight / Infant, Small for Gestational Age / Infants, Premature / Newborn Infants1
1CompletedTreatmentErythemas / Pain1
1CompletedTreatmentHealthy Volunteers1
1CompletedTreatmentKnee Osteoarthritis (Knee OA)1
1CompletedTreatmentLeukemia Acute Myeloid Leukemia (AML)1
1CompletedTreatmentPsoriasis Vulgaris (Plaque Psoriasis)1
1RecruitingBasic ScienceSleep Restriction1
1RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)1
1RecruitingTreatmentAcute Lymphoblastic Leukemia With Failed Remission / Acute Lymphoblastic Leukemia, in Relapse1
1RecruitingTreatmentHeroin Dependence / Opioid Use Disorders1
1RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML)1
1RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome1
1RecruitingTreatmentLymphoblastic Leukemia, Acute, Childhood / Lymphoma, Lymphoblastic / Peripheral T-Cell Lymphoma (PTCL)1
1Unknown StatusTreatmentOvarian Epithelial Cancer1
1WithdrawnBasic ScienceDiabetes, Diabetes Mellitus Type 11
1, 2Active Not RecruitingTreatmentInhospital Cardiac Arrest1
1, 2CompletedDiagnosticSystemic Lupus Erythematosus (SLE)1
1, 2CompletedTreatment21-Hydroxylase Deficiency / Adrenogenital Syndrome / Congenital Adrenal Hyperplasia (CAH)1
1, 2CompletedTreatmentCardiac Arrest1
1, 2CompletedTreatmentRecurrent Childhood Acute Lymphoblastic Leukemia1
1, 2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)1
1, 2RecruitingTreatmentAddison's Disease / Adrenal Hyperplasia Congenital1
1, 2RecruitingTreatmentAdult Burkitt Lymphoma / B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma / Lymphoma, Large B-Cell, Diffuse (DLBCL) / MYC Gene Mutation / Plasmablastic Lymphoma1
1, 2TerminatedBasic ScienceRenin Angiotensin1
1, 2TerminatedTreatmentAdenocarcinoma, Prostate / Recurrent Prostate Carcinoma / Stage III Prostate Cancer / Stage IV Prostate Cancer1
1, 2TerminatedTreatmentAnaplastic Large Cell Lymphoma / Recurrent Childhood Anaplastic Large Cell Lymphoma1
1, 2TerminatedTreatmentProstate Cancer1
2Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)2
2Active Not RecruitingTreatmentLymphoma, Lymphoblastic1
2Active Not RecruitingTreatmentProstate Cancer1
2CompletedNot AvailablePostoperative Complications / Postoperative Pancreatitis1
2CompletedPreventionChronic Lung Disease of Prematurity1
2CompletedPreventionChronic Lung Disease of Prematurity / Encephalomalacia / Premature Births1
2CompletedPreventionMemory Disturbances1
2CompletedSupportive CareAdvanced Malignant Neoplasm / Dermatologic Complication / Dermatologic Complications / Neoplasms, Malignant1
2CompletedTreatmentAcute Lymphocytic Leukemia (ALL)1
2CompletedTreatmentAcute Respiratory Distress Syndrome (ARDS) / Multiple Organ Failure1
2CompletedTreatmentAdenocarcinoma, Prostate / Prostate Cancer1
2CompletedTreatmentAdrenal Hyperplasia, Congenital1
2CompletedTreatmentAdrenal Insufficiency / Congenital Adrenal Hyperplasia (CAH) / Excess Androgen1
2CompletedTreatmentAngioedema1
2CompletedTreatmentB-cell Adult Acute Lymphoblastic Leukemia / B-cell Childhood Acute Lymphoblastic Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Lymphoblastic Lymphoma / T-cell Adult Acute Lymphoblastic Leukemia / T-cell Childhood Acute Lymphoblastic Leukemia1
2CompletedTreatmentBlood Cancers / CLL / Graft Versus Host Disease (GVHD) / Hodgkins Disease (HD) / Leukemias / Malignancies / NHL / Smith-Magenis Syndrome1
2CompletedTreatmentBlood and Marrow Transplant (BMT) / Multiple Myeloma (MM) / Transplantation, Autologous / Transplantation, Homologous1
2CompletedTreatmentCardiac Output, Low1
2CompletedTreatmentChildhood Burkitt Lymphoma / Childhood Diffuse Large Cell Lymphoma / Childhood Immunoblastic Large Cell Lymphoma / Stage I Childhood Large Cell Lymphoma / Stage I Childhood Small Noncleaved Cell Lymphoma / Stage II Childhood Large Cell Lymphoma / Stage II Childhood Small Noncleaved Cell Lymphoma / Stage III Childhood Large Cell Lymphoma / Stage III Childhood Small Noncleaved Cell Lymphoma / Stage IV Childhood Large Cell Lymphoma / Stage IV Childhood Small Noncleaved Cell Lymphoma / Untreated Childhood Acute Lymphoblastic Leukemia1
2CompletedTreatmentHemorrhoids1
2CompletedTreatmentJet Lag Syndrome1
2CompletedTreatmentLeukemia, Mast-Cell / Mantle Cell Lymphoma (MCL)1
2CompletedTreatmentLeukemias1
2CompletedTreatmentLymphohistiocytosis, Hemophagocytic1
2CompletedTreatmentOpioid Dependence1
2CompletedTreatmentPaediatric Sepsis / Pediatric Sepsis / Sepsis1
2CompletedTreatmentProstate Cancer1
2CompletedTreatmentPrurigo Nodularis1
2CompletedTreatmentRash1
2CompletedTreatmentRecurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Lymphoblastic Lymphoma / T-cell Childhood Acute Lymphoblastic Leukemia1
2Not Yet RecruitingBasic ScienceAdolescent Development / Borderline Personality Disorder (BPD)1
2Not Yet RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Childhood Cancers / Down Syndrome (DS)1
2Not Yet RecruitingTreatmentCongenital Adrenal Hyperplasia (CAH)1
2RecruitingTreatmentAcute Leukemias of Ambiguous Lineage / Childhood B Acute Lymphoblastic Leukemia / KMT2A Gene Rearrangement / Mixed Phenotype Acute Leukemia (MPAL)1
2RecruitingTreatmentAcute Lymphocytic Leukemia (ALL) / Adult Lymphoblastic Lymphoma1
2RecruitingTreatmentAdrenal Hyperplasia, Congenital1
2RecruitingTreatmentApomorphine-induced Skin Reactions / Parkinson's Disease (PD)1
2RecruitingTreatmentColorectal Cancers / Head and Neck Carcinoma1
2RecruitingTreatmentCritically Ill / Sepsis / Shock, Septic / Vasoplegic Syndrome1
2RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML)1
2RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndromes1
2RecruitingTreatmentProstate Cancer1
2RecruitingTreatmentRecurrent B-Cell Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood B-Lymphoblastic Lymphoma1
2RecruitingTreatmentSevere Sepsis / Shock, Septic1
2TerminatedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukemia, B-Cell / Leukemia, T-Cell / Non-Hodgkin's Lymphoma (NHL)1
2TerminatedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Lymphoma, Lymphoblastic1
2TerminatedTreatmentAcute Lymphocytic Leukemia (ALL) / Leukemia Acute Myeloid Leukemia (AML) / Mixed Lineage Acute Leukemia1
2TerminatedTreatmentBlood and Marrow Transplant (BMT) / Diffuse Large B-Cell / Lymphoma, B-Cell / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Lymphomas: Non-Hodgkin / Malignant Lymphoma, Non-Hodgkin / Non-Hodgkin's Lymphoma (NHL)1
2TerminatedTreatmentCastration-Resistant Prostate Cancer (CRPC)1
2TerminatedTreatmentLeukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndromes (MDS)1
2TerminatedTreatmentPhobic Disorders1
2Unknown StatusTreatmentAcute Lymphoblastic Leukaemias (ALL)1
2Unknown StatusTreatmentAddison's Disease1
2Unknown StatusTreatmentCirrhosis With Ascites1
2Unknown StatusTreatmentInjuries, Whiplash1
2Unknown StatusTreatmentLeukemias1
2, 3Active Not RecruitingTreatmentAsphyxia / Hypoxic-Ischaemic Encephalopathy1
2, 3Active Not RecruitingTreatmentChildhood B Acute Lymphoblastic Leukemia / Childhood Burkitt Leukemia / Childhood Diffuse Large Cell Lymphoma / Mediastinal (Thymic) Large B-Cell Lymphoma / Stage III Childhood Large Cell Lymphoma / Stage IV Childhood Large Cell Lymphoma1
2, 3CompletedPreventionInjuries, Multiple1
2, 3CompletedTreatmentAddison's Disease1
2, 3CompletedTreatmentAdrenal Insufficiency1
2, 3CompletedTreatmentAdult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
2, 3RecruitingTreatmentLeft Ventricular Remodeling / ST Segment Elevation Myocardial Infarction (STEMI)1
2, 3RecruitingTreatmentOsteoarthritis, Shoulder1
2, 3Unknown StatusTreatmentMortality / Ventilations, Mechanical1
3Active Not RecruitingTreatmentCardiovascular Insufficiency / Infant, Newborn, Diseases1
3CompletedSupportive CareCardiac Toxicity / Leukemias / Malignant Lymphomas1
3CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL)1
3CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Undifferentiated Leukemia (AUL) / Childhood T Acute Lymphoblastic Leukemia / T-cell Childhood Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3CompletedTreatmentAlcohol Craving / Stress, Physiological / Stress, Psychological1
3CompletedTreatmentAlopecia Areata (AA)1
3CompletedTreatmentCardiac Arrest1
3CompletedTreatmentChildhood Acute Erythroleukemia (M6) / Childhood Acute Megakaryocytic Leukemia (M7) / Childhood Acute Monoblastic Leukemia (M5a) / Childhood Acute Monocytic Leukemia (M5b) / Childhood Acute Myeloblastic Leukemia With Maturation (M2) / Childhood Acute Myeloblastic Leukemia Without Maturation (M1) / Childhood Acute Myelomonocytic Leukemia (M4) / Childhood Myelodysplastic Syndromes / Chronic Myelomonocytic Leukemia / De Novo Myelodysplastic Syndromes / Refractory Anemia / Refractory Anemia With Excess Blasts / Refractory Anemia With Excess Blasts in Transformation / Refractory Anemia With Ringed Sideroblasts / Secondary Myelodysplastic Syndromes / Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies1
3CompletedTreatmentChronic Lung Disease of Prematurity1
3CompletedTreatmentCoagulation Dysfunction in Septic Shock / Hemodynamic Improvement Induced by Hydrocortisone1
3CompletedTreatmentHealthy Volunteers1
3CompletedTreatmentHerpes Labialis1
3CompletedTreatmentLeukemias / Malignant Lymphomas1
3CompletedTreatmentLeukemias / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
3CompletedTreatmentNeonatal Hypotension1
3CompletedTreatmentOral Submucous Fibrosis1
3CompletedTreatmentOtitis Externa1
3CompletedTreatmentPatient Admitted in Reanimation1
3CompletedTreatmentProstate Cancer1
3CompletedTreatmentPsoriasis Vulgaris (Plaque Psoriasis)1
3CompletedTreatmentSepsis / Shock, Septic1
3CompletedTreatmentSevere Sepsis1
3CompletedTreatmentShock, Septic3
3Not Yet RecruitingSupportive CareSepsis1
3Not Yet RecruitingTreatmentCongenital Adrenal Hyperplasia (CAH)1
3Not Yet RecruitingTreatmentImmune Thrombocytopenia / Purpura, Thrombocytopenic, Idiopathic1
3RecruitingPreventionChronic Lung Disease of Prematurity / Infant, Small for Gestational Age / Infants, Premature / Newborn Infants / Very Low Birth Weight Infant1
3RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / B Acute Lymphoblastic Leukemia / B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 / BCR-ABL1 Fusion Protein Expression / Minimal Residual Disease / Philadelphia Chromosome Positive / T Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / B Acute Lymphoblastic Leukemia / Central Nervous System Leukemia / Cognitive Side Effects of Cancer Therapy / Neurotoxicity Syndrome / Osteonecrosis / Pain / Ph-Like Acute Lymphoblastic Leukemia / Testicular Leukemia / Therapy-Related Toxicity / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3RecruitingTreatmentAcute Lymphoblastic Leukemia, Pediatric1
3RecruitingTreatmentB Acute Lymphoblastic Leukemia / Central Nervous System Leukemia / Cognitive Side Effects of Cancer Therapy / Neurotoxicity Syndrome / Osteonecrosis / Pain / Testicular Leukemia / Therapy-Related Toxicity / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3RecruitingTreatmentB Acute Lymphoblastic Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Lymphoblastic Leukemia1
3RecruitingTreatmentCommunity Acquired Pneumonia (CAP)1
3RecruitingTreatmentCongenital Adrenal Hyperplasia (CAH)2
3RecruitingTreatmentLiver Cirrhosis1
3RecruitingTreatmentSevere Septic Syndrome (Severe Sepsis and Septic Shock) Diagnosed and Treated by Mobile Intensive Care Unit1
3SuspendedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Adult T Acute Lymphoblastic Leukemia / Ann Arbor Stage II Adult Lymphoblastic Lymphoma / Ann Arbor Stage II Childhood Lymphoblastic Lymphoma / Ann Arbor Stage III Adult Lymphoblastic Lymphoma / Ann Arbor Stage III Childhood Lymphoblastic Lymphoma / Ann Arbor Stage IV Adult Lymphoblastic Lymphoma / Ann Arbor Stage IV Childhood Lymphoblastic Lymphoma / Childhood T Acute Lymphoblastic Leukemia / Stage II Adult Lymphoblastic Lymphoma / Stage II Childhood Lymphoblastic Lymphoma / Stage II Contiguous Adult Lymphoblastic Lymphoma / Stage II Non-Contiguous Adult Lymphoblastic Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Childhood Lymphoblastic Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Childhood Lymphoblastic Lymphoma / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3TerminatedTreatmentEvidence of Liver Transplantation / Transplantations1
3TerminatedTreatmentInfluenza in Humans / Viral Pneumonia1
3TerminatedTreatmentProstatic Neoplasms1
3Unknown StatusTreatmentLow Back Pain (LBP)1
4Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)1
4CompletedNot AvailableMinor burns1
4CompletedBasic ScienceFeeling Anxious1
4CompletedBasic ScienceHealthy Volunteers1
4CompletedBasic ScienceStress Disorders, Posttraumatic1
4CompletedPreventionPostoperative Inflammatory Response1
4CompletedPreventionPosttraumatic Stress Disorders / Systemic Inflammatory Response Syndrome (SIRS)1
4CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL)1
4CompletedTreatmentAdrenal Insufficiency1
4CompletedTreatmentAsthma Bronchial1
4CompletedTreatmentAtopic Dermatitis (AD)1
4CompletedTreatmentAtopic Dermatitis (AD) / Psoriasis1
4CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)1
4CompletedTreatmentCoronary Artery Disease / Mitral Valve Regurgitation1
4CompletedTreatmentHip Injuries1
4CompletedTreatmentHyperglycemias1
4CompletedTreatmentKnee Replacement Surgery1
4CompletedTreatmentRheumatic Diseases1
4CompletedTreatmentShock1
4CompletedTreatmentShock, Septic1
4CompletedTreatmentSnake Bites1
4Enrolling by InvitationTreatmentAdrenal Insufficiency1
4Enrolling by InvitationTreatmentCorticotropin Deficiency / Fasting1
4Enrolling by InvitationTreatmentGranuloma / Tracheostomy care1
4RecruitingPreventionNeoplasms, Pancreatic / Pancreatic Fistula1
4RecruitingSupportive CareRheumatoid Arthritis1
4RecruitingTreatmentAtopic Dermatitis (AD)1
4RecruitingTreatmentCommunity Acquired Pneumonia (CAP)1
4RecruitingTreatmentCritical Illness / Fluid Overload / Sepsis / Shock, Septic1
4RecruitingTreatmentFunction of Renal Transplant1
4RecruitingTreatmentGranulomatous Mastitis1
4RecruitingTreatmentUlcerative Colitis (UC)2
4TerminatedNot AvailableAsthma Bronchial1
4TerminatedTreatmentPartial Corticotrope Insufficiency1
4TerminatedTreatmentShock, Septic1
4Unknown StatusTreatmentAcute Respiratory Distress Syndrome (ARDS) / Adrenal Insufficiency1
4Unknown StatusTreatmentCrohn's Disease (CD)1
4Unknown StatusTreatmentPituitary Neoplasms / Postsurgical craniopharyngioma1
4WithdrawnTreatmentAdrenal Insufficiency / Sepsis1
4WithdrawnTreatmentAtopic Dermatitis (AD)1
4WithdrawnTreatmentPhimosis1
4WithdrawnTreatmentPost-Traumatic Stress Disorder (PTSD)1
Not AvailableActive Not RecruitingPreventionDialysis Hypotension1
Not AvailableActive Not RecruitingSupportive CareSjögren's Syndrome1
Not AvailableCompletedNot AvailableAnxiety Disorders / Major Depressive Disorder (MDD)1
Not AvailableCompletedNot AvailableDependence, Cocaine1
Not AvailableCompletedNot AvailableHeroin Dependence / Learning and Memory1
Not AvailableCompletedNot AvailableKnee Osteoarthritis (Knee OA)1
Not AvailableCompletedNot AvailableSepsis1
Not AvailableCompletedBasic ScienceIntrusive Memories1
Not AvailableCompletedBasic SciencePosttraumatic Stress Disorders1
Not AvailableCompletedPreventionFevers / Hemodynamics Instability / Hypothermia / Idiopathic orthostatic hypotension1
Not AvailableCompletedScreeningOther Diseases or Conditions1
Not AvailableCompletedTreatmentAcute Lung Injury (ALI) / Acute Respiratory Distress Syndrome (ARDS) / Severe Sepsis / Shock, Septic1
Not AvailableCompletedTreatmentAddison's Disease1
Not AvailableCompletedTreatmentAddison's Disease / BMI >30 kg/m21
Not AvailableCompletedTreatmentAdrenal Hyperplasia, Congenital1
Not AvailableCompletedTreatmentAtopic Dermatitis (AD)1
Not AvailableCompletedTreatmentHeart Arrest1
Not AvailableCompletedTreatmentHeart Disease Congenital Complex1
Not AvailableCompletedTreatmentPTSD1
Not AvailableCompletedTreatmentPhobic Disorders1
Not AvailableCompletedTreatmentPituitary Adenomas / Pituitary Diseases1
Not AvailableCompletedTreatmentTotal Hip Replacement1
Not AvailableRecruitingBasic ScienceBorderline Personality Disorder (BPD) / PTSD1
Not AvailableRecruitingPreventionPost Traumatic Stress Disorder (PTSD)1
Not AvailableRecruitingTreatmentAtopic Dermatitis (AD)1
Not AvailableRecruitingTreatmentFatty Acids, Nonesterified / Hydrocortisone / Hypopituitarism / Insulin Sensitivity / Lipids1
Not AvailableRecruitingTreatmentIntussusception1
Not AvailableRecruitingTreatmentPlantar fascial fibromatosis1
Not AvailableRecruitingTreatmentShock, Septic1
Not AvailableSuspendedNot AvailableSome Studies Shows That the Steroid Can Reduce the Injury of the I/R of the Liver1
Not AvailableTerminatedNot AvailableNonvalvular Atrial Fibrillation1
Not AvailableTerminatedPreventionBrain Death1
Not AvailableTerminatedTreatmentNecrotizing Enterocolitis1
Not AvailableTerminatedTreatmentPosttraumatic Stress Disorders1
Not AvailableUnknown StatusPreventionPosttraumatic Stress Disorders1
Not AvailableUnknown StatusTreatmentChronic Obstructive Pulmonary Disease (COPD)1
Not AvailableUnknown StatusTreatmentMajor Depressive Disorder (MDD)1
Not AvailableUnknown StatusTreatmentPTSD1
Not AvailableWithdrawnTreatmentPost-Traumatic Stress Disorder (PTSD)1

Pharmacoeconomics

Manufacturers
  • Hi tech pharmacal co inc
  • Allergan herbert div allergan inc
  • Del ray laboratories inc
  • Salix pharmaceuticals inc
  • Bayer pharmaceuticals corp
  • Monarch pharmaceuticals inc
  • Valeant pharmaceuticals international
  • Westwood squibb pharmaceuticals inc
  • C and m pharmacal inc
  • Pharmaceutical assoc inc div beach products
  • Actavis mid atlantic llc
  • Alpharma us pharmaceuticals division
  • Altana inc
  • Ambix laboratories div organics corp america
  • Everylife
  • E fougera div altana inc
  • G and w laboratories inc
  • Ingram pharmaceutical co
  • Ivax pharmaceuticals inc
  • Naska pharmacal co inc div rugby darby group cosmetics
  • Perrigo new york inc
  • Pharmaderm div altana inc
  • Pharmafair inc
  • Stiefel laboratories inc
  • Syosset laboratories inc
  • Taro pharmaceuticals usa inc
  • Teva pharmaceuticals usa inc
  • Topiderm inc
  • Usl pharma inc
  • Vintage pharmaceuticals inc
  • Whiteworth towne paulsen inc
  • Sanofi aventis us llc
  • Coria laboratories ltd
  • Medicis pharmaceutical corp
  • Paddock laboratories inc
  • Ani pharmaceuticals inc
  • Teva pharmaceuticals usa
  • Healthpoint ltd
  • Allergan herbert skin care div allergan inc
  • Pharmacia and upjohn co
  • Baker norton pharmaceuticals inc
  • Solvay pharmaceuticals
  • Beta dermaceuticals inc
  • Bluline laboratories inc
  • Heran pharmaceutical inc
  • Mericon industries inc
  • Perrigo co
  • Pfizer global research development
  • Carolina medical products co
  • Dermik laboratories div aventis pharmaceuticals inc
  • Torch laboratories inc
  • X gen pharmaceuticals inc
  • Jsj pharmaceuticals llc
  • Pfizer laboratories div pfizer inc
  • Barr laboratories inc
  • Elkins sinn div ah robins co inc
  • John j ferrante
  • Impax laboratories inc
  • Inwood laboratories inc sub forest laboratories inc
  • Lannett co inc
  • Nexgen pharma inc
  • Panray corp sub ormont drug and chemical co inc
  • Parke davis div warner lambert co
  • Purepac pharmaceutical co
  • Roxane laboratories inc
  • Sandoz inc
  • Stiefel a gsk co
  • Vintage pharmaceuticals llc
  • Watson laboratories inc
  • West ward pharmaceutical corp
  • Merck and co inc
  • Pfipharmecs div pfizer inc
  • Schwarz pharma inc
  • Able laboratories inc
  • Hr cenci laboratories inc
  • Ferndale laboratories inc
  • Akorn inc
  • Bel mar laboratories inc
  • Colgate oral pharmaceuticals inc
  • Taro pharmaceutical industries ltd
  • Triax pharmaceuticals llc
  • Yamanouchi europe bv
  • Savage laboratories inc div altana inc
  • Abbott laboratories pharmaceutical products div
  • Abbott laboratories hosp products div
  • Hospira inc
  • Abraxis pharmaceutical products
  • Baxter healthcare corp anesthesia and critical care
  • International medication systems ltd
  • Taro pharmaceuticals inc
  • Ranbaxy laboratories inc
Packagers
  • Actavis Group
  • Advanced Pharmaceutical Services Inc.
  • AG Marin Pharmaceuticals
  • Alaven Pharmaceutical
  • Alcon Laboratories
  • Amerisource Health Services Corp.
  • Ani Pharmaceuticals
  • Anip Acquisition Co.
  • Arbor Pharmaceuticals Incorporated
  • A-S Medication Solutions LLC
  • Avidas Pharmaceuticals
  • Bay Pharma Inc.
  • Bayer Healthcare
  • Bergen Brunswig
  • Beta Dermaceuticals
  • Bio Pharm Inc.
  • Bristol-Myers Squibb Co.
  • C.O. Truxton Inc.
  • Cardinal Health
  • Carlisle Laboratories Inc.
  • Carolina Medical Products Co.
  • Chattem Chemicals Inc.
  • Co Med Pharmaceuticals Inc.
  • Colgate Oral
  • Combe Inc.
  • Consolidated Midland Corp.
  • Contract Pharm
  • Crown Laboratories Inc.
  • Cutis Pharma Inc.
  • Cypress Pharmaceutical Inc.
  • Darby Dental Supply Co. Inc.
  • Del Ray Dermatology
  • Dermik Labs
  • DispenseXpress Inc.
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Dofs Laboratories
  • DPT Laboratories Ltd.
  • DSC Laboratories
  • E. Fougera and Co.
  • ECR Pharmaceuticals
  • Elkins-Sinn Inc.
  • Enterprises Importfab Inc.
  • Ferndale Labs
  • G & W Labs
  • Genesis Pharmaceutical Inc.
  • Gertz
  • H and H Laboratories
  • H.J. Harkins Co. Inc.
  • Harmony Laboratories Inc.
  • Hi Tech Pharmacal Co. Inc.
  • Hospira Inc.
  • Inyx Usa Ltd.
  • JHP Pharmaceuticals LLC
  • Johnson & Johnson Healthcare
  • JSJ Pharmaceuticals Inc.
  • Kaiser Foundation Hospital
  • Keltman Pharmaceuticals Inc.
  • Lake Erie Medical and Surgical Supply
  • Lehigh Valley Technologies Inc.
  • Lyne Laboratories Inc.
  • Major Pharmaceuticals
  • Mallinckrodt Inc.
  • Martin Surgical Supply
  • Meda AB
  • Mikart Inc.
  • Murfreesboro Pharmaceutical Nursing Supply
  • National Vitamin Company
  • Nexgen Pharma Inc.
  • Nycomed Inc.
  • Paddock Labs
  • Palmetto Pharmaceuticals Inc.
  • Patheon Inc.
  • Perrigo Co.
  • Person & Covey
  • Pfizer Inc.
  • Pharmacia Inc.
  • Pharmaderm
  • Pharmedix
  • Physician Partners Ltd.
  • Physicians Total Care Inc.
  • Preferred Pharmaceuticals Inc.
  • Professional Co.
  • Prometic Pharma Inc.
  • Qualitest
  • Ranbaxy Laboratories
  • Rebel Distributors Corp.
  • Redpharm Drug
  • Resource Optimization and Innovation LLC
  • Rising Pharmaceuticals
  • River's Edge Pharmaceuticals
  • Rouses Point Pharmaceuticals LLC
  • Salix Pharmaceuticals
  • Sandhills Packaging Inc.
  • Sandoz
  • Sanofi-Aventis Inc.
  • Schwarz Pharma Inc.
  • Solvay Pharmaceuticals
  • Southwood Pharmaceuticals
  • Stanley Pharmaceuticals Ltd.
  • Stat Rx Usa
  • Stat Scripts LLC
  • Summers Labs
  • Suppositoria Laboratories Inc.
  • Taro Pharmaceuticals USA
  • Teva Pharmaceutical Industries Ltd.
  • Topiderm Inc.
  • Triax Pharmaceuticals LLC
  • UCB Pharma
  • United Pharmaceuticals
  • United Research Laboratories Inc.
  • Universal Laboratories Inc.
  • Upsher Smith Laboratories
  • Veratex Corp.
  • Vertical Pharmaceuticals Inc.
  • Vintage Pharmaceuticals Inc.
  • West-Ward Pharmaceuticals
  • Wockhardt Ltd.
  • WraSer Pharmaceuticals
  • Wyeth Pharmaceuticals
Dosage forms
FormRouteStrength
CreamTopical5 mg/g
SolutionTopical1 g/100g
LotionTopical.01 g/g
OintmentTopical1.02 g/100g
Cream; jellyTopical1 %
CreamTopical.01 g/g
CreamTopical.284 g/28.4g
CreamTopical10 mg/g
SuspensionAuricular (otic)
SprayTopical1 g/100g
CreamTopical1 g/100g
SprayTopical10 g/mL
OintmentTopical10 mg
TabletOral10 mg
TabletOral20 mg
EnemaRectal100 mg
Enema; suspensionRectal100 mg
OintmentTopical100 g/g
OintmentTopical
SuspensionTopical
OintmentTopical10 mg/g
GelTopical10 mg/g
LiquidTopical10 mg/mL
LotionTopical1 g/100g
LotionTopical10 mg/g
Solution / dropsOphthalmic
GelTopical1 mg/g
LotionTopical1 mg/mL
LotionTopical10 mg/mL
LotionTopical.75 g/100mL
CreamTopical.284 g/287.4g
CreamTopical1 g/100mL
CreamTopical2.5 %
SolutionTopical2.5 %
KitOral
OintmentTopical10 mg/mL
OintmentTopical1 mL/100mL
LotionTopical1 g/mL
Aerosol, sprayTopical1.13 g/113g
CreamTopical1 h/100g
CreamTopical10 mg/mL
CreamTopical25 mg/g
EnemaRectal100 mg/60mL
GelTopical1 g/100g
LotionTopical25 mg/mL
OintmentTopical25 mg/g
OintmentTopical25 mg/1
OintmentTopical5 mg/g
ShampooTopical1 g/100mL
SuspensionRectal100 mg/60mL
TabletOral10 mg/1
TabletOral20 mg/1
TabletOral5 mg/1
SolutionAuricular (otic)
CreamTopical500 mg
CreamTopical1 g
CreamTopical1.02 g/100g
CreamTopical0.5 %
CreamTopical5 mg
CreamTopical10 mg
CreamTopical
OintmentTopical0.5 %
OintmentTopical1 %
CreamTopical.5 g/100g
Powder, for solutionIntramuscular; Intravenous100 mg
Powder, for solutionIntramuscular; Intravenous250 mg
Powder, for solutionIntramuscular; Intravenous500 mg
Powder, for solutionIntramuscular; Intravenous1 g
CreamTopical140 mg/14g
LotionTopical1 g/100mL
LotionTopical1.02 g/100g
OintmentTopical1 g/100g
LiquidTopical5 mg/mL
LiquidTopical9 mg/mL
SprayTopical10 mg/mL
CreamTopical.009 g/1
Solution / dropsAuricular (otic)
Suspension / dropsAuricular (otic)
OintmentOphthalmic
SuspensionOphthalmic
Kit
LotionTopical5 mg/g
Kit
LipstickTopical.005 g/g
LotionTopical.025 mg/2.5mL
GelTopical
CreamTopical7.5 g/100mL
CreamTopical1 mg/g
LiquidTopical.28 mg/100mL
OintmentRectal
SuppositoryRectal
OintmentRectal; Topical750 mg
SuppositoryRectal10 mg
CreamTopical.51 g/100g
SprayTopical500 g/g
CreamTopical1 mg/100mL
LotionTopical2.5 %
LiquidTopical10 mg/g
LiquidTopical
LiquidTopical1 g/100mL
LotionTopical1 mL/100mL
SolutionTopical25 mg/mL
LotionTopical1 %
LotionTopical
CreamTopical10 mg/L
SprayTopical10 g/L
Prices
Unit descriptionCostUnit
Locoid Lipocream 0.1% Cream 60 gm Tube335.36USD tube
Cortifoam 90 mg Foam 15 gm Can239.99USD can
Locoid 0.1% Solution 60ml Bottle233.15USD bottle
Locoid Lipocream 0.1% Cream 45 gm Tube200.98USD tube
Locoid 0.1% Cream 45 gm Tube183.83USD tube
Locoid 0.1% Ointment 45 gm Tube174.86USD tube
Pandel 0.1% Cream 45 gm Tube161.37USD tube
Pandel 0.1% Cream 15 gm Tube138.56USD tube
Proctocort 1% Cream 28.35 gm Tube127.51USD tube
Anusol-HC 2.5% Cream 30 gm Tube106.45USD tube
Locoid Lipocream 0.1% Cream 15 gm Tube85.41USD tube
Texacort 2.5% Solution 30ml Bottle85.41USD bottle
Cortisporin 3.5-10000-1 Solution 10ml Bottle84.33USD bottle
Proctofoam HC 1-1% Foam 10 gm Can81.9USD can
Cortisporin 3.5-10000-1 Suspension 10ml Bottle79.55USD bottle
Locoid 0.1% Solution 20ml Bottle79.28USD bottle
Cortisporin 1% Ointment 15 gm Tube75.09USD tube
Locoid 0.1% Cream 15 gm Tube67.49USD tube
Hydrocortisone Ace-Pramoxine 2.5-1% Cream 28.35 gm Tube64.75USD tube
Locoid 0.1% Ointment 15 gm Tube62.04USD tube
Hydrocortisone Valerate 0.2% Ointment 60 gm Tube56.74USD tube
Hydrocortisone 2.5% Lotion 59 gm Bottle55.61USD bottle
Westcort 0.2% Ointment 60 gm Tube55.0USD tube
Cortisporin 0.5-0.5-10000 Cream 7.5 gm Tube54.37USD tube
Westcort 0.2% Ointment 15 gm Tube50.99USD tube
Hydrocortisone Butyrate 0.1% Cream 45 gm Tube49.43USD tube
Hydrocortisone Valerate 0.2% Ointment 45 gm Tube48.73USD tube
Hydrocortisone 2.5% Lotion 59ml Bottle47.47USD bottle
Westcort 0.2% Ointment 45 gm Tube46.97USD tube
Hydrocortisone Valerate 0.2% Cream 60 gm Tube44.99USD tube
Hydrocortisone Valerate 0.2% Cream 45 gm Tube33.99USD tube
Ala Scalp 2% Lotion 29.6ml Bottle30.99USD bottle
Hydrocortisone Valerate 0.2% Ointment 15 gm Tube30.56USD tube
Westcort 0.2% Cream 15 gm Tube25.99USD tube
Hydrocortisone Valerate 0.2% Cream 15 gm Tube19.99USD tube
Cortisporin eye drops19.74USD ml
Solu-Cortef 1 g/vial17.55USD vial
Hydrocortisone 1% Lotion 118ml Bottle15.99USD bottle
Hydrocortisone Acetate 12 25 mg Suppository Box15.01USD box
Hydrocortisone 2.5% Ointment 28.35 gm Tube13.68USD tube
Hydrocortisone 2.5% Cream 30 gm Tube13.67USD tube
Colocort 100 mg/60ml Enema 60ml Bottle13.15USD bottle
Hydrocortisone 100 mg/60ml Enema 60ml Bottle12.6USD bottle
Hydrocortisone 0.5% Cream 28.35 gm Tube11.99USD tube
Hydrocortisone 1% Cream 15 gm Tube11.99USD tube
Hydrocortisone 1% Cream 28 gm Tube11.99USD tube
Hydrocortisone Acetate 1-1% Ointment 30 gm Tube11.99USD tube
Solu-Cortef 500 mg/vial10.47USD vial
Hydrocortisone hemisucc powder9.9USD g
Cortifoam 10% aerosol9.35USD g
Hydrocortisone Sod. Succinate 1 g/vial9.01USD vial
Solu-cortef (pf) 250 mg vial8.58USD vial
Cortisporin-tc ear susp8.3USD ml
Cortisporin ear suspension7.86USD ml
Solu-Cortef 250 mg/vial7.05USD vial
Cortenema (100 mg/60Ml) 100 mg/enm Enema6.96USD enema
Proctofoam-hc foam6.77USD g
Cortifoam 10 % Foam6.14USD g
Hycort (100 mg/60Ml) 100 mg/enm Enema5.79USD enema
Cortamed 2.5 % Ointment5.67USD g
Hydrocortisone Sod. Succinate 500 mg/vial5.34USD vial
Hydrocortisone powder5.19USD g
Solu-cortef (pf) 100 mg vial4.85USD vial
Solu-cortef 100 mg vial4.63USD vial
Proctocort 1% cream4.37USD g
Pandel 0.1% cream4.34USD g
Locoid 0.1% lipocream4.3USD g
Solu-Cortef 100 mg/vial4.07USD vial
Locoid 0.1% cream3.92USD g
Hydrocortisone Sod. Succinate 250 mg/vial3.56USD vial
Hydrocortisone ss 250 mg vial3.5USD vial
Anusol-hc 2.5% cream3.45USD g
Hydrocortisone acet powder3.15USD g
Proctofoam2.89USD g
A-hydrocort 100 mg vial2.42USD each
Proctocream-hc 2.5% cream2.17USD g
Hydrocortisone Sod. Succinate 100 mg/vial2.1USD vial
Hydrocortisone val 0.2% cream2.07USD g
Hytone 2.5% cream1.46USD g
Hydrocortisone buty 0.1% cream1.31USD g
First hydrocort 10% gel1.18USD g
Westcort 0.2% cream1.17USD g
Procto-kit 1% cream1.08USD g
Ala-scalp hp 2% lotion1.03USD ml
Cortef 20 mg tablet0.9USD tablet
Proctosol-hc 2.5% cream0.89USD g
Proctozone-hc 2.5% cream0.83USD g
Orabase plain paste0.77USD g
Hydrocortisone 2.5% lotion0.6USD ml
Cortef 10 mg tablet0.55USD tablet
Orabase-b 20% gel0.55USD g
Hydrocortisone 2.5% cream0.53USD g
Hydrocortisone 10 mg tablet0.52USD tablet
Cortef 5 mg tablet0.45USD tablet
Ala-cort 1% cream0.43USD g
Hydrocortisone 5 mg tablet0.38USD tablet
Corticaine 0.5% cream0.37USD g
Hydrocortisone 20 mg tablet0.32USD tablet
Prevex Hc 1 % Occlusive Cream0.3USD g
Emo-Cort 2.5 % Cream0.26USD g
Preparation h 1% cream0.24USD g
Tucks hydrocortisone ointment0.24USD g
Emo-Cort 2.5 % Lotion0.23USD g
Emo-Cort Scalp 2.5 % Lotion0.22USD g
Colocort 100 mg enema0.21USD ml
Cortenema 100 mg enema0.21USD ml
Sarna Hc 2.5 % Lotion0.2USD g
Emo-Cort 1 % Cream0.19USD g
Balneol lotion0.18USD ml
Emo-Cort 1 % Lotion0.18USD g
Lanacort 1% cool creme0.18USD g
Hyderm 0.5 % Cream0.18USD g
Hytone 1% cream0.17USD g
Cortoderm Mild 0.5 % Ointment0.15USD g
Beta hc 1% lotion0.14USD ml
Cortizone-10 1% spray0.14USD ml
Hydroval 0.2 % Cream0.13USD g
Hydroval 0.2 % Ointment0.13USD g
Aquanil hc 1% lotion0.12USD ml
Hydrocortisone plus 12 1% crm0.12USD g
Scalpicin 3% liquid0.12USD ml
Slender cortisol capsule0.12USD capsule
Cortaid 1% spray0.1USD ml
Sarna Hc 1 % Lotion0.1USD g
Hydrocortisone 0.5% cream0.08USD g
Hydrocortisone 1% cream0.08USD g
Uniderm moisturizer0.05USD ml
Cortoderm Regular 1 % Ointment0.04USD g
Hyderm 1 % Cream0.04USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5635497No1994-06-032014-06-03Us
US7378405No2006-12-192026-12-19Us
US7981877No2005-01-232025-01-23Us
USRE39264No1996-08-022016-08-02Us
US6514980No1999-01-242019-01-24Us
US7223387No2001-07-242021-07-24Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)220 °CPhysProp
water solubility320 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP1.61HANSCH,C ET AL. (1995)
logS-2.97ADME Research, USCD
Caco2 permeability-4.66ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.199 mg/mLALOGPS
logP1.79ALOGPS
logP1.28ChemAxon
logS-3.3ALOGPS
pKa (Strongest Acidic)12.59ChemAxon
pKa (Strongest Basic)-2.8ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area94.83 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity97.4 m3·mol-1ChemAxon
Polarizability39.45 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9918
Blood Brain Barrier+0.9383
Caco-2 permeable-0.5096
P-glycoprotein substrateSubstrate0.7861
P-glycoprotein inhibitor INon-inhibitor0.7847
P-glycoprotein inhibitor IINon-inhibitor0.8383
Renal organic cation transporterNon-inhibitor0.7463
CYP450 2C9 substrateNon-substrate0.8496
CYP450 2D6 substrateNon-substrate0.9138
CYP450 3A4 substrateSubstrate0.7407
CYP450 1A2 substrateNon-inhibitor0.9406
CYP450 2C9 inhibitorNon-inhibitor0.9072
CYP450 2D6 inhibitorNon-inhibitor0.9418
CYP450 2C19 inhibitorNon-inhibitor0.9253
CYP450 3A4 inhibitorNon-inhibitor0.8902
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9095
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.9597
BiodegradationNot ready biodegradable0.925
Rat acute toxicity1.8914 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.95
hERG inhibition (predictor II)Non-inhibitor0.584
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (2.96 KB)
Spectra
SpectrumSpectrum TypeSplash Key
GC-MS Spectrum - GC-MS (2 MEOX; 3 TMS)GC-MSsplash10-0f7o-3930000000-b7b43b2fc9f20acfd20b
GC-MS Spectrum - GC-MSGC-MSsplash10-0f7o-3930000000-b7b43b2fc9f20acfd20b
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-052f-2910000000-2625335a031486ecb302
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-IT , negativeLC-MS/MSsplash10-015a-0189000000-61afe49a8d4a96aae3f9
MS/MS Spectrum - Linear Ion Trap , negativeLC-MS/MSsplash10-00lu-0149000000-b95a11b27f7e7d44dd51
MS/MS Spectrum - Linear Ion Trap , negativeLC-MS/MSsplash10-001l-0019000000-4c4924e6ac472ad52886
MS/MS Spectrum - , negativeLC-MS/MSsplash10-001j-0259000000-fda4e876e9ef04015946
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03di-0009000000-cc8188e19dbdd6210b77
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-07r1-1985000000-b6d756bd554367393be3
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00dj-1930000000-120dc8893cc4709c1f6b
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00dm-2910000000-d1f01e1bce5fe0108f40
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-05tf-3900000000-4ffd79c22013fe5479b6
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-054o-4900000000-fdbed869a0cadc21b64b
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-002f-7900000000-dac7b2c5b3f8e8b85086
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-016u-7900000000-3a770c3819f82ea45841
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-016r-9800000000-d261cf7141fbf30715f5
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-056r-0289000000-9a48511b5c3d5fa404e9
MS/MS Spectrum - , positiveLC-MS/MSsplash10-03di-0759000000-b337a46ecfd6de91776b
MS/MS Spectrum - , positiveLC-MS/MSsplash10-05fs-3940000000-2bf712a915c3a2c100a2

Taxonomy

Description
This compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Hydroxysteroids
Direct Parent
21-hydroxysteroids
Alternative Parents
Gluco/mineralocorticoids, progestogins and derivatives / 20-oxosteroids / 3-oxo delta-4-steroids / 17-hydroxysteroids / 11-beta-hydroxysteroids / Delta-4-steroids / Cyclohexenones / Tertiary alcohols / Alpha-hydroxy ketones / Secondary alcohols
show 4 more
Substituents
Progestogin-skeleton / 21-hydroxysteroid / 20-oxosteroid / Pregnane-skeleton / 3-oxo-delta-4-steroid / 3-oxosteroid / Oxosteroid / 11-beta-hydroxysteroid / 11-hydroxysteroid / 17-hydroxysteroid
show 16 more
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
3-oxo steroid, 11beta-hydroxy steroid, 17alpha-hydroxy steroid, glucocorticoid, 20-oxo steroid, 21-hydroxy steroid, C21-steroid (CHEBI:17650) / Pregnane and derivatives [Fig], Glucocorticoids, C21 steroids (gluco/mineralocorticoids, progestogens) and derivatives (C00735) / C21 steroids (gluco/mineralocorticoids, progestogins) and derivatives (LMST02030001)

Targets

Details
1. Glucocorticoid receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Zinc ion binding
Specific Function
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modula...
Gene Name
NR3C1
Uniprot ID
P04150
Uniprot Name
Glucocorticoid receptor
Molecular Weight
85658.57 Da
References
  1. Grossman R, Yehuda R, Golier J, McEwen B, Harvey P, Maria NS: Cognitive effects of intravenous hydrocortisone in subjects with PTSD and healthy control subjects. Ann N Y Acad Sci. 2006 Jul;1071:410-21. [PubMed:16891588]
  2. Rautanen A, Eriksson JG, Kere J, Andersson S, Osmond C, Tienari P, Sairanen H, Barker DJ, Phillips DI, Forsen T, Kajantie E: Associations of body size at birth with late-life cortisol concentrations and glucose tolerance are modified by haplotypes of the glucocorticoid receptor gene. J Clin Endocrinol Metab. 2006 Nov;91(11):4544-51. Epub 2006 Aug 8. [PubMed:16895953]
  3. Hammer F, Stewart PM: Cortisol metabolism in hypertension. Best Pract Res Clin Endocrinol Metab. 2006 Sep;20(3):337-53. [PubMed:16980198]
  4. Shaw JR, Gabor K, Hand E, Lankowski A, Durant L, Thibodeau R, Stanton CR, Barnaby R, Coutermarsh B, Karlson KH, Sato JD, Hamilton JW, Stanton BA: Role of glucocorticoid receptor in acclimation of killifish (Fundulus heteroclitus) to seawater and effects of arsenic. Am J Physiol Regul Integr Comp Physiol. 2007 Feb;292(2):R1052-60. Epub 2006 Oct 12. [PubMed:17038445]
  5. Sher L: Combined dexamethasone suppression-corticotropin-releasing hormone stimulation test in studies of depression, alcoholism, and suicidal behavior. ScientificWorldJournal. 2006 Oct 31;6:1398-404. [PubMed:17086345]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Structural molecule activity
Specific Function
Plays important roles in the innate immune response as effector of glucocorticoid-mediated responses and regulator of the inflammatory process. Has anti-inflammatory activity (PubMed:8425544). Play...
Gene Name
ANXA1
Uniprot ID
P04083
Uniprot Name
Annexin A1
Molecular Weight
38713.855 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Sato-Matsumura KC, Matsumura T, Nakamura H, Sawa H, Nagashima K, Koizumi H: Membrane expression of annexin I is enhanced by calcium and TPA in cultured human keratinocytes. Arch Dermatol Res. 2000 Oct;292(10):496-9. [PubMed:11142771]
  4. White MV, Igarashi Y, Lundgren JD, Shelhamer J, Kaliner M: Hydrocortisone inhibits rat basophilic leukemia cell mediator release induced by neutrophil-derived histamine releasing activity as well as by anti-IgE. J Immunol. 1991 Jul 15;147(2):667-73. [PubMed:1712816]
  5. Serres M, Viac J, Comera C, Schmitt D: Expression of annexin I in freshly isolated human epidermal cells and in cultured keratinocytes. Arch Dermatol Res. 1994;286(5):268-72. [PubMed:8060156]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Steroid binding
Specific Function
Catalyzes the conversion of cortisol to the inactive metabolite cortisone. Modulates intracellular glucocorticoid levels, thus protecting the nonselective mineralocorticoid receptor from occupation...
Gene Name
HSD11B2
Uniprot ID
P80365
Uniprot Name
Corticosteroid 11-beta-dehydrogenase isozyme 2
Molecular Weight
44126.06 Da
References
  1. Furstenberger C, Vuorinen A, Da Cunha T, Kratschmar DV, Saugy M, Schuster D, Odermatt A: The anabolic androgenic steroid fluoxymesterone inhibits 11beta-hydroxysteroid dehydrogenase 2-dependent glucocorticoid inactivation. Toxicol Sci. 2012 Apr;126(2):353-61. doi: 10.1093/toxsci/kfs022. Epub 2012 Jan 23. [PubMed:22273746]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Steroid delta-isomerase activity
Specific Function
3-beta-HSD is a bifunctional enzyme, that catalyzes the oxidative conversion of Delta(5)-ene-3-beta-hydroxy steroid, and the oxidative conversion of ketosteroids. The 3-beta-HSD enzymatic system pl...
Gene Name
HSD3B1
Uniprot ID
P14060
Uniprot Name
3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1
Molecular Weight
42251.25 Da
References
  1. Bhatia C, Oerum S, Bray J, Kavanagh KL, Shafqat N, Yue W, Oppermann U: Towards a systematic analysis of human short-chain dehydrogenases/reductases (SDR): Ligand identification and structure-activity relationships. Chem Biol Interact. 2015 Jun 5;234:114-25. doi: 10.1016/j.cbi.2014.12.013. Epub 2014 Dec 16. [PubMed:25526675]

Enzymes

Details
1. Cytochrome P450 3A4
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
Inducer
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Ekins S, Bravi G, Wikel JH, Wrighton SA: Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. J Pharmacol Exp Ther. 1999 Oct;291(1):424-33. [PubMed:10490933]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid 11-beta-monooxygenase activity
Specific Function
Has steroid 11-beta-hydroxylase activity. In addition to this activity, the 18 or 19-hydroxylation of steroids and the aromatization of androstendione to estrone have also been ascribed to cytochro...
Gene Name
CYP11B1
Uniprot ID
P15538
Uniprot Name
Cytochrome P450 11B1, mitochondrial
Molecular Weight
57572.44 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid 11-beta-monooxygenase activity
Specific Function
Preferentially catalyzes the conversion of 11-deoxycorticosterone to aldosterone via corticosterone and 18-hydroxycorticosterone.
Gene Name
CYP11B2
Uniprot ID
P19099
Uniprot Name
Cytochrome P450 11B2, mitochondrial
Molecular Weight
57559.62 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Androgen binding
Specific Function
Functions as an androgen transport protein, but may also be involved in receptor mediated processes. Each dimer binds one molecule of steroid. Specific for 5-alpha-dihydrotestosterone, testosterone...
Gene Name
SHBG
Uniprot ID
P04278
Uniprot Name
Sex hormone-binding globulin
Molecular Weight
43778.755 Da
References
  1. Khoromi S, Muniyappa R, Nackers L, Gray N, Baldwin H, Wong KA, Matheny LA, Moquin B, Rainer A, Hill S, Remaley A, Johnson LL, Max MB, Blackman MR: Effects of chronic osteoarthritis pain on neuroendocrine function in men. J Clin Endocrinol Metab. 2006 Nov;91(11):4313-8. Epub 2006 Aug 15. [PubMed:16912126]
  2. Stroud LR, Solomon C, Shenassa E, Papandonatos G, Niaura R, Lipsitt LP, Lewinn K, Buka SL: Long-term stability of maternal prenatal steroid hormones from the National Collaborative Perinatal Project: still valid after all these years. Psychoneuroendocrinology. 2007 Feb;32(2):140-50. Epub 2007 Jan 31. [PubMed:17270355]
  3. Lombardi G, Mondaini N, Macchiarella A, Del Popolo G: Female sexual dysfunction and hormonal status in spinal cord injured (SCI) patients. J Androl. 2007 Sep-Oct;28(5):722-6. Epub 2007 May 9. [PubMed:17494102]
  4. Shifren JL, Desindes S, McIlwain M, Doros G, Mazer NA: A randomized, open-label, crossover study comparing the effects of oral versus transdermal estrogen therapy on serum androgens, thyroid hormones, and adrenal hormones in naturally menopausal women. Menopause. 2007 Nov-Dec;14(6):985-94. [PubMed:17507833]
  5. Rizzo L, Dobrovsky V, Danilowicz K, Kral M, Cross G, Serra HA, Bruno OD: Low-dose glucocorticoids in hyperandrogenism. Medicina (B Aires). 2007;67(3):247-52. [PubMed:17628912]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Steroid binding
Specific Function
Major transport protein for glucocorticoids and progestins in the blood of almost all vertebrate species.
Gene Name
SERPINA6
Uniprot ID
P08185
Uniprot Name
Corticosteroid-binding globulin
Molecular Weight
45140.49 Da
References
  1. Henley DE, Lightman SL: New insights into corticosteroid-binding globulin and glucocorticoid delivery. Neuroscience. 2011 Apr 28;180:1-8. doi: 10.1016/j.neuroscience.2011.02.053. Epub 2011 Mar 1. [PubMed:21371536]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25. [PubMed:12699389]
  2. Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, Roden MM, Belas F, Chaudhary AK, Roden DM, Wood AJ, Wilkinson GR: Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res. 1999 Mar;16(3):408-14. [PubMed:10213372]
  3. Yates CR, Chang C, Kearbey JD, Yasuda K, Schuetz EG, Miller DD, Dalton JT, Swaan PW: Structural determinants of P-glycoprotein-mediated transport of glucocorticoids. Pharm Res. 2003 Nov;20(11):1794-803. [PubMed:14661924]
  4. Ueda K, Okamura N, Hirai M, Tanigawara Y, Saeki T, Kioka N, Komano T, Hori R: Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J Biol Chem. 1992 Dec 5;267(34):24248-52. [PubMed:1360010]
  5. Orlowski S, Mir LM, Belehradek J Jr, Garrigos M: Effects of steroids and verapamil on P-glycoprotein ATPase activity: progesterone, desoxycorticosterone, corticosterone and verapamil are mutually non-exclusive modulators. Biochem J. 1996 Jul 15;317 ( Pt 2):515-22. [PubMed:8713080]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both fro...
Gene Name
ABCG2
Uniprot ID
Q9UNQ0
Uniprot Name
ATP-binding cassette sub-family G member 2
Molecular Weight
72313.47 Da
References
  1. Imai Y, Asada S, Tsukahara S, Ishikawa E, Tsuruo T, Sugimoto Y: Breast cancer resistance protein exports sulfated estrogens but not free estrogens. Mol Pharmacol. 2003 Sep;64(3):610-8. [PubMed:12920197]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibit...
Gene Name
SLCO1A2
Uniprot ID
P46721
Uniprot Name
Solute carrier organic anion transporter family member 1A2
Molecular Weight
74144.105 Da
References
  1. Kanai N, Lu R, Bao Y, Wolkoff AW, Schuster VL: Transient expression of oatp organic anion transporter in mammalian cells: identification of candidate substrates. Am J Physiol. 1996 Feb;270(2 Pt 2):F319-25. [PubMed:8779893]
  2. Bossuyt X, Muller M, Hagenbuch B, Meier PJ: Polyspecific drug and steroid clearance by an organic anion transporter of mammalian liver. J Pharmacol Exp Ther. 1996 Mar;276(3):891-6. [PubMed:8786566]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Curator comments
Cortisol demonstrated substrate activity in vitro using human OAT3 expressed on Xenopus Laevis.
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenad...
Gene Name
SLC22A8
Uniprot ID
Q8TCC7
Uniprot Name
Solute carrier family 22 member 8
Molecular Weight
59855.585 Da
References
  1. VanWert AL, Gionfriddo MR, Sweet DH: Organic anion transporters: discovery, pharmacology, regulation and roles in pathophysiology. Biopharm Drug Dispos. 2010 Jan;31(1):1-71. doi: 10.1002/bdd.693. [PubMed:19953504]

Drug created on June 13, 2005 07:24 / Updated on August 15, 2018 09:44